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« La théorie, c'est quand on sait tout et que rien ne fonctionne. 
La pratique, c'est quand tout fonctionne et que personne ne sait pourquoi. 
Ici, nous avons réuni théorie et pratique : 
Rien ne fonctionne... et personne ne sait pourquoi ! » 
 
Albert Einstein 
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Introduction générale 
Le développement de nouvelles techniques de délivrance du médicament permet 
d’adapter la stratégie d’administration des substances actives en fonction de leurs propriétés 
physico-chimiques et de la cible thérapeutique envisagée. En particulier, l’introduction des 
nanomédecines (nanotechnologies appliquées au domaine de la médecine) dans les années 60 
a été la source d’importants espoirs pour le traitement de maladies graves telles que le cancer. 
Cependant, bien qu’une quinzaine de ces nanoformulations aient été mises sur le marché, le 
développement des nanomédecines en général a rencontré plusieurs verrous technologiques. 
En effet, les nanomédicaments présentent souvent un très faible taux de charge en substance 
active, relarguent parfois de manière massive et précoce le principe actif (phénomène de « 
burst release ») et peuvent exhiber une certaine toxicité due au matériel de vectorisation utilisé. 
De plus, la transposition d’échelle pour une production industrielle se révèle parfois trop 
compliquée et/ou coûteuse. 
La stratégie de « squalénisation », mise au point depuis 2004 par l’équipe du Professeur 
Couvreur, a permis de lever certains de ces verrous. En effet, cette technique consiste à coupler 
une substance active à un dérivé du squalène – un lipide endogène, biocompatible et 
biodégradable, précurseur du cholestérol – afin de former un bioconjugué ayant la capacité de 
s’auto-assembler en nanoparticules d’une centaine de nanomètres de diamètre en milieu 
aqueux. Ces nanomédicaments présentent notamment un fort taux de charge en principe actif, 
une très bonne biocompatibilité, une pharmacocinétique nettement améliorée par rapport à la 
substance active libre et une biodistribution beaucoup plus ciblée de celle-ci. 
L’application de cette stratégie à l’adénosine, une molécule au potentiel thérapeutique 
important mais limité par un temps de demi-vie plasmatique extrêmement court, a fourni des 
résultats particulièrement prometteurs dans le cadre du traitement de l’ischémie cérébrale et 
du traumatisme de la moëlle épinière. L’objectif de cette thèse était donc de faire progresser le 
développement pré-clinique de ces nanoparticules d’adénosine-squalène selon deux axes 
majeurs : l’étude de leur mécanisme d’action et l’optimisation de leur formulation. 
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Dans une première partie bibliographique, nous présenterons les différentes 
associations créées jusqu’à aujourd’hui entre l’adénosine et les lipides. Nous aborderons 
notamment la délivrance de l’adénosine et de ses dérivés phosphorylés via des liposomes, puis 
nous décrirons les différents bioconjugués lipidiques formés à base d’adénosine ainsi que leurs 
capacités d’auto-organisation supramoléculaire. 
Le premier chapitre expérimental décrira ensuite les résultats obtenus lors de l’étude in 
vitro du mécanisme d’action des nanoparticules d’adénosine-squalène. L’interaction directe 
entre l’adénosine-squalène (sous forme de nanoparticule ou de bioconjugué) et les récepteurs 
à l’adénosine a été étudiée grâce à une expérience de déplacement d’un radioligand. Cette 
interaction s’étant révélée négligeable, l’étude de l’adénosine-squalène en tant que prodrogue 
a été réalisée sur des hépatocytes. L’adénosine-squalène est en effet retrouvé en quantités 
importantes dans le foie après injection des nanoparticules par voie intraveineuse chez la 
souris. Ainsi, l’internalisation par les cellules HepG2 de nanoparticules d’adénosine-squalène 
radiomarquées ou fluorescentes, suivie du relargage d’adénosine, ont été étudiés. Cette étude a 
permis de mettre en lumière la formation d’un réservoir intracellulaire d’adénosine due à 
l’internalisation puis à l’accumulation des nanoparticules d’adénosine-squalène. 
Le second chapitre expérimental présentera enfin l’optimisation des conditions de 
lyophilisation des nanoparticules d’adénosine-squalène. La bonne conservation de leurs 
propriétés physico-chimiques a été vérifiée par différentes techniques analytiques, dont la 
diffusion dynamique de la lumière, la diffraction des rayons X et des neutrons aux petits angles, 
ou encore la microscopie à force atomique. L’influence de la présence d’éthanol résiduel (utilisé 
lors de la formulation) sur le résultat de la lyophilisation est un point intéressant qui a été 
soulevé lors de cette étude. La lyophilisation a permis une bonne stabilité des nanoparticules 
dans le temps avec une reconstitution très aisée de celles-ci, les rendant ainsi très facilement 
manipulables en vue d’une administration en cas d’urgence. 
 
L’ensemble de ces travaux constitue ainsi une avancée significative dans le 
développement pré-clinique des nanoparticules d’adénosine-squalène, par la mise en lumière 
de leur mécanisme d’action et l’établissement d’une nouvelle formulation, plus pratique et 
reproductible. 
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General Introduction 
Ongoing advances in drug delivery help to adapt the administration strategy of the active 
ingredient taking into account its physico-chemical properties as well as the therapeutic target. 
In particular, the introduction of nanomedicines (or nanotechnologies applied to medicine) in 
the 1960’s has brought hope for enhancing the effectiveness of the treatments against severe 
diseases such as cancer, through a better targeted approach. However, even though around 
fifteen nanoformulations are already used in the clinic, the development of nanomedicines in 
general has suffered from serious drawbacks.  Indeed, nanomedicines often present extremely 
low drug loadings, may prematurely and massively release the active compound before 
reaching the target (phenomenon of “burst release”) and exhibit some toxicity due, among 
other things, to the vector per se. Moreover, scaling-up the production for clinical needs is 
sometimes challenging and/or too costly. 
The so-called « squalenoylation » strategy, developed since 2004 by Pr. Couvreur’s team, 
has overcome some of these limitations. This original technology consists in coupling an active 
ingredient with a derivative of squalene – an endogenous, biocompatible and biodegradable 
lipid which is a precursor of cholesterol – to form bioconjugates able to self-assemble as 
nanoparticles of around 100 nm of diameter in aqueous medium. The resulting nanomedicines 
generally present high drug loadings, very good biocompatibility, enhanced pharmacokinetics 
compared to the free drug as well as a more targeted biodistribution. 
This strategy was applied to adenosine, a molecule which high therapeutic potential is 
severely impaired by its very short half-life in blood circulation. Squalene-adenosine 
nanoparticles have shown extremely promising results for the treatment of cerebral ischemia 
and spinal cord injury. Hence, the objective of this thesis was to further develop squalene-
adenosine nanoparticles at the pre-clinical stage, pursuing two major goals: studying their 
mechanism of action and optimizing their formulation. 
 
First, in a bibliographic part, we will present the different associations which have so far 
been designed between adenosine and lipids. More precisely, we will address liposomal 
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delivery of adenosine and its phosphorylated derivatives, before describing adenosine-based 
lipid bioconjugates and their supramolecular self-assemblies. 
The first experimental chapter will then describe the mechanism of action of squalene-
adenosine nanoparticles through in vitro studies. Direct interaction between squalene-
adenosine (whether as a nanoparticle or bioconjugate) with adenosine receptors was studied 
by radioligand displacement assays. As this interaction was found to be negligible, we therefore 
investigated whether squalene-adenosine could act as a prodrug. This mechanism was studied 
on hepatocytes, as high quantities of squalene-adenosine are found in the liver after 
intravenous injection of squalene-adenosine nanoparticles in mice. HepG2 cellular uptake of 
radio- or fluorescently labeled squalene-adenosine nanoparticles was studied, as well as the 
resulting adenosine release. This study highlighted the presence of an adenosine intracellular 
reservoir due to the internalization and intracellular accumulation of squalene-adenosine 
nanoparticles. 
Finally, the second experimental chapter will present the optimization of squalene-
adenosine nanoparticles formulation through the use of the best freeze-drying conditions. The 
preservation of the nanoparticles’ physico-chemical properties was checked by different 
analytical techniques, such as dynamic light scattering, small-angle X-ray or neutrons scattering 
or atomic force microscopy. In addition, the presence of residual ethanol (used during the 
nanoparticles’ formulation) was shown to influence the lyophilization success. Of note, this 
finding had rarely been studied before. In that respect, the freeze-drying of nanoparticles led to 
their long-term stability as well as to their easy and rapid reconstitution in ready-to-use 
nanoparticulate suspension which could thus prove quite convenient for administration in 
emergency cases. 
 
Overall, this work represents a major step forward the pre-clinical development of 
squalene-adenosine nanoparticles by bringing to light their mechanism of action and 
establishing a new, easy-to-use and reproducible formulation. 
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Adenosine and lipids: a forced marriage 
or a love match? 
 
Abstract 
Adenosine is a fascinating compound, crucial in many biochemical processes: this 
ubiquitous nucleoside serves as an essential brick for building RNA, is also a component 
of ATP and regulates numerous pathophysiological mechanisms via binding to four 
extracellular receptors. Due to its hydrophilic nature, it belongs to a different world than 
where lipids come from, and has no affinity for them. Since the 1970’s, however, new 
discoveries have emerged and prompted the scientists to associate adenosine with the 
lipid family, especially via liposomal preparations and bioconjugation. This seems to be an 
arranged marriage, but could it turn into a true love match? This review clustered all types 
of unions which were established between adenosine and lipids. Even though exciting 
supramolecular structure were observed with adenosine-lipid conjugates, as well as, with 
liposomal preparations which resulted in promising pre-clinical results, the translation of 
these technologies to the clinic is still limited. 
 
Adenosine is a nucleoside involved in multiple essential biochemical processes both intra- and 
extracellularly (Figure 1). In the cell, adenosine can be phosphorylated into adenosine 
monophosphate (AMP), which is used by the cell as an RNA building block. This 
phosphorylation process can be repeated in order to generate adenosine triphosphate (ATP), 
the “molecular currency” furnishing energy to the cell. ATP can also be converted by adenylyl 
cyclase (AC) into cyclic AMP (cAMP), a very common second messenger which triggers 
intracellular signal transduction cascade. Outside the cell, adenosine regulates essential 
processes by binding to four G-protein-coupled receptors: A1, A2A, A2B and A3 [1], which govern 
major pathophysiological functions. Equilibrative nucleoside transporters (ENTs), which are 
widely expressed by the cells [2], maintain the balance between intra- and extracellular 
concentrations of adenosine. Under pathological conditions, extracellular adenosine 
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concentrations dramatically rise due to the release of abundant intracellular ATP by damaged 
cells [3] and its prompt transformation into adenosine by ectonucleotidases CD39 and CD73.   
 
 
Adenosine is a hydrophilic molecule that has no affinity with lipids. Like Romeo and 
Juliet, they come from two separate worlds that rarely mingle. But, if forced to join, would they 
repel each other, accommodate or start a fusional relationship? Scientific discoveries in the 70’s 
and 80’s encouraged research on that topic.  
The development of liposomes for drug delivery in the early 1970’s [4] was seen by some 
specialists as a very suitable match for adenosine and its derivatives. Indeed, adenosine and 
ATP have very short plasmatic half-life [5,6] due to their degradation by plasmatic enzymes and 
rapid uptake by erythrocytes and endothelial cells, which could be circumvented by liposomal 
encapsulation. First proposed applications were the delivery of liposomal ATP to treat rat 
ischemic brains [7] and liposomal adenosine to examine its effect on the contraction of rat 
Figure 1 Intracellular and extracellular adenosine. In the cell, adenosine is degraded by adenosine 
deaminase (ADA) into inosine or phosphorylated by adenosine kinase (AdK) into adenosine mono-
phosphate (AMP), di-phosphate (ADP) or tri-phosphate (ATP), which is used as substrate by adenylyl 
cyclase (AC) for cyclic AMP (cAMP) formation. Outside the cell, adenosine binds four receptors involved 
in various pathophysiological processes. 
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aortic smooth muscle cells [8]. As will be presented in the first part of this review, the first 
matchmakers’ intuition was accurate and liposomal forms of adenosine, ATP and even ADP 
have been developed and studied since this consensual marriage with expected successful 
outcomes.  
Completely independently, a few naturally occurring nucleolipids were discovered in 
the 1970’s, such as tunicamycins, which were isolated from Streptomyces lysosuperficus [9]. 
This drove chemists to create multiple artificial nucleolipids a few years later, including 
adenosine nucleolipids like adenosine-5’-alkylphosphates [10]. There were two main 
rationales for studying such adenosine nucleolipids: (i) authors saw them as possible 
intermediates in enzymatic reactions involving ATP and lipids and wanted to study their 
physiological significance [10,11], or (ii) they wanted to explore the existence of hydrophobic 
regions in the active sites of ATP-dependent enzymes [12].  
With a totally different mindset, a third rationale for developing adenosine nucleolipids 
was established in the late 1980’s. Adenosine congeners were functionalized by covalently 
attaching lipids at a permissive site (e.g. N6 or C2 positions of adenosine) with the idea to alter 
the drug distribution and metabolism in vivo while conserving good binding properties without 
any prior cleavage [13,14]. 
Even though these approaches have opened the field of adenosine nucleolipids and given 
some interesting results, no author really anticipated that this forced marriage would become 
a perfect love match between adenosine and lipids. Nucleolipids, and adenosine nucleolipids in 
particular, present remarkable properties that will be exposed in the second part of this review.  
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I. Adenosine and adenosine derivates loaded liposomes 
Liposomes are lipid-bilayer vesicles made of combinations of natural or/and synthetic lipids. 
These lipids are perfectly biocompatible and biodegradable and have already been used as 
excipients in numerous vaccines. As a result, liposomes can be used as safe delivery systems for 
both hydrophilic and hydrophobic molecules. Up until now, more than 15 liposomal 
formulations already reached the market, Doxil® being the most well-known among them [15]. 
When adenosine, ADP or ATP are loaded into the liposomes’ hydrophilic core, they are 
protected from the blood stream and their pharmacokinetics and biodistributions are 
completely modified, offering new therapeutic possibilities. Table 1 describes the composition 
and size of the liposomes that will be described in this part, as well as their drug loading and/or 
encapsulation efficiency when available. Regrettably, not all reports provide a full and 
comprehensive characterization of their liposomal system, which leads to uncertainties in 
terms of dosage, especially because liposomal formulation often present very poor drug 
loadings.  
  Introduction bibliographique 
18 
Table 1 Adenosine, ADP and ATP-loaded liposomes. 
Drug loaded Lipid composition 
Liposome 
size (nm) 
Drug loading 
(µmol drug / 
µmol lipid) 
Encapsulation 
efficiency (%) 
Therapeutic 
target 
References 
Adenosine 
DSPC:DSPG:chol 168 ± 18 n.d. 12.9 
Inflammation [16] DSPC:chol 206 ± 40 n.d. 8.6 
DSPC:DODAB:Chol 202 ± 27 n.d. 10.5 
HSPC:chol:DSPE-PEG 134 ± 21 n.d. n.d. 
Myocardial 
ischemia 
[17] 
Soybean oil:PC:chol:glycerin n.d. n.d. n.d. Osteoarthritis [18] 
ADP 
DMPC:chol:DHSG:DSPE-
PEG:H12-PEG-Glu2C18 
240 ± 68 n.d. n.d. 
Hemostasis [19–22] 
DPPC:chol:DHSG:DSPE-
PEG:H12-PEG-Glu2C18 
285 ± 78 n.d. n.d. 
DSPC:chol:DHSG:DSPE-
PEG:H12-PEG-Glu2C18 
298 ± 107 n.d. n.d. 
ATP 
PC:chol:SM4 ~ 140 ≤ 0.39 n.d. Cerebral 
ischemia 
[7,23] 
PC:chol n.d. n.d. n.d. [24] 
PS 
~ 100 
n.d. n.d. 
Retinal ischemia [25,26] PC n.d. n.d. 
PS:PC n.d. n.d. 
PC:chol:stearylamine > 2000 0.32 ± 0.02 n.d. 
Myocardial 
ischemia 
[27] 
PC:chol:DSPE-PEG:DOTAP ~ 200 c.a. 0.40 n.d. [28,29] 
PC:chol:DSPE-PEG:2G4-PEG–PE ~ 200 n.d. n.d. [30] 
PC:chol:DSPE-PEG:DOTAP:2G4-
PEG–PE 
190 ± 45 c.a. 0.40 n.d. [31] 
PC:chol n.d. n.d. 8 
Liver ischemia 
[32] 
PC:chol:PG ~ 200 0.35 ± 0.06 n.d. [33,34] 
PC:chol 
~ 100 
n.d. n.d. 
[35,36] 
PC:chol:PG n.d. n.d. 
PC:chol:ODA ≤ 0.07 ± 0.01 n.d. 
PC:chol:DOTAP n.d. n.d. 
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PC:chol:DOTAP:DOPE n.d. n.d. 
PC:chol:DOTAP:Lac-10-chol 0.04 ± 0.01 n.d. 
PC:chol:DOTAP:DOPE:Lac-10-
chol 
0.03 ± 0.01 n.d. 
DPPC:chol:PEG ~ 120 0.33 ± 0.11 n.d. 
Islet 
transplantation 
[37] 
DSPC:DSPE-PEG:chol n.d. n.d. n.d. 
Intestinal 
ischemia 
[38] 
VitaSol n.d. n.d. n.d. 
Wound healing 
[39] 
ATPv n.d. n.d. n.d. [40] 
DOPC:DOPC-E n.d. n.d. n.d. [41] 
PC:DOTAP 120 - 160 n.d. n.d. [42–45] 
ATP + 
pentobarbital + 
suramin 
DOPE:CHEMS:PEG-PE ~ 150 n.d. n.d. 
Cerebral 
ischemia 
[46] 
 
CHEMS: cholesteryl hemisuccinate; Chol: cholesterol; DHSG: 1,5-dihexadecyl-N-succinyl-l-glutamate; DODAB: dimethyldioctadecyl ammonium 
bromide; DOPE: 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine; DOPC: 1,2-dioleoyl-sn-glycero-3-phosphocholine; DOPC-E: 1,2-dioleoyl-sn-glycero-
3-ethylphosphocholine; DOTAP: 1,2-dioleoyl-3-trimethyl-ammonium-propane; DPPC: 1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine; DSPC: 1,2-
distearoyl-sn-glycero-3-phosphocholine; DSPE-PEG: 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-n-[methoxy(polyethylene glycol)]; DSPG: 1,2-
distearoyl-sn-glycero-3-phosphorylglycerol; H12-PEG-Glu2C18: dodecapeptide HHLGGAKQAGDV-polyethylene glycol-Glutamate 2C18; HSPC: 
hydrogenated soy phosphatidyl choline; n.d.: not determined; ODA: octadecylamine; PC: phosphatidylcholine; PEG-PE: polyethylene glycol-
phosphatidylethanolamine; PG: phosphatidylglycerol; PS: phosphatidylserine; SM4: sulfatide.
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1) Liposomal adenosine 
The main objective of adenosine encapsulation into liposomes is to prolong its half-life in the 
blood stream. Liposomal formulations can also enhance the quantity of active drug at the site 
of action by passive or active targeting. 
Based on this background knowledge, Gutman et al. developed adenosine loaded 
liposomes to target inflammation [16]. They showed that negatively charged liposomes 
composed of 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), distearoyl-
phosphatidylglycerol (DSPG) and cholesterol could be prepared by reverse phase evaporation 
method and loaded with adenosine (reaching a drug loading charge of 12.9 %), and that these 
monodisperse liposomes of around 170 nm of diameter were internalized by human monocytes 
and reduced inflammation in vitro. Regrettably, the only parameter assessed in vivo was the 
absence of adenosine loaded liposomes toxicity on monocytes, whereas their influence on 
inflammation was not monitored. 
Another approach for passive targeting via liposomal formulation was developed by 
Takahama et al. for myocardial ischemia and reperfusion [17]. It is known that cellular 
permeability is enhanced in the zone of infarct due to the disruption of the vascular endothelial 
integrity. As a result, the authors decided to prepare PEGylated adenosine liposomes with 
prolonged circulation time for reaching higher concentration of adenosine in the target zone. 
For this purpose, neutral monodisperse liposomes were prepared by the hydration method, 
with hydrogenated soy phosphatidylcholine, cholesterol and 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-n-[methoxy(polyethylene glycol)-2000] (DSPE-PEG2000). The use of 
fluorescent liposomes showed that they indeed accumulated in the necrotic area, which 
correlated with a prolonged residence time of liposomal radiolabeled adenosine in the same 
zone. This led to a reduction of the infarct size which was not associated with usual adenosine 
side effects (hypotension and bradycardia), confirming the advantage of using liposomal 
delivery. 
Very recently, Corciulo et al. developed the idea of using liposomal adenosine for 
treating osteoarthritis [18], based on the fact that extracellular adenosine downregulation was 
known to be implicated in the development of the disease, more specifically via its interaction 
with A2A receptor. Unexpectedly, they observed that injection of A2AR agonists did not protect 
rats against a model of post-traumatic osteoarthritis. Hence, they decided to load adenosine in 
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liposomes made of soybean oil, phosphatidylcholine, cholesterol and glycerin and injected them 
locally in the joint. Using this formulation of adenosine, they witnessed important prevention 
and protection effects against the disease, with reduced joint swelling, cartilage and joint 
protection, as well as lowered OARSI scores, and demonstrated that these effects depended on 
A=R activation. Even though these results constitute a promising pre-clinical proof-of-concept, 
it seems unfortunate that liposomal formulations were so poorly defined (basic information on 
their composition can only be found in the corresponding patent [47]) and scarcely 
characterized in this work, with no mention of physico-chemical parameters. 
2) Liposomal ADP 
An original liposomal ADP system has been developed for 10 years in Takeoka’s lab for platelet 
substitution. Pegylated liposomes were loaded with ADP in the intraliposomal aqueous core 
and functionalized with a fibrinogen γ-chain peptide. This peptide corresponded to the 
carboxyl terminal 12 amino acids of the fibrinogen γ-chain and is a ligand for glycoprotein 
IIb/IIIa receptors which are expressed on activated platelets at the site of injury. As a result, 
these “H12-(ADP)-liposomes” specifically accumulated within the sites of injuries after 
intravenous injection [22] and reduced the bleeding time in thrombocytopenic rats [21] and 
rabbits [20,48] by playing two different roles: (i) they enhanced platelet aggregation via cross-
linking between activated platelets thanks to their functionalization with the fibrinogen γ-chain 
peptide and (ii) they enhanced platelet activation by releasing ADP, which acts through platelet 
surface receptors P2Y1, P2Y12 or P2X1. Interestingly, authors could modulate this ADP release 
by tuning the vesicles lamellarity and flexibility [21]. 
Recently, this team made a brilliant conceptual and experimental move: instead of 
continuing to consider ADP only as a drug for platelet activation, they started looking at it as an 
adenosine prodrug. This led them to evaluate the pharmacological efficacy of H12-(ADP)-
liposomes on blast lung injury, where ADP would be useful in treating the hemorrhage, while 
adenosine would exert anti-inflammatory protective effects [48] (Figure 2). They obtained an 
important increase in mice survival after lung injury in the group treated with H12-(ADP)-
liposomes, going with reduced tissue damage/hemorrhage and inflammation. Moreover, they 
proved the implication of adenosine in this phenomenon, as treatment with A2A and A2B 
antagonists abrogated the beneficial effects of the H12-(ADP)-liposomes. 
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3) Liposomal ATP 
Like adenosine, ATP cannot be efficiently delivered intracellularly by itself. It is very rapidly 
metabolized in the bloodstream and the hydrophilic nature of this nucleoside prevents from 
crossing cell membranes. As a result, ATP-loaded liposomes have been used for several decades 
to improve ATP delivery (Figure 3A). 
As ATP is the main energy currency in the cell, intracellular ATP delivery has mainly 
been used for pathologies involving a phenomenon of energy failure. The main application has 
been ischemia, i.e. the lack of blood supply in a tissue, leading to a shortage in oxygen, decreased 
cell metabolism and ATP depletion. Ischemic insults can virtually affect any organ or tissue, the 
most common and severe cases being heart, brain and liver ischemia. 
Figure 2 Hypothetic mechanism of action of H12-(ADP)-liposomes. (1) H12-(ADP)-liposomes 
accumulate at the site of injury by binding glycoprotein (GP) IIb/IIIa on activated platelets. (2) This 
also enhances platelet cross-linking, as the same liposome presents several fibrinogen γ-chain 
peptides moieties on its surface and can therefore bind several activated platelets. (3) ADP released 
from the liposomes (4) further activates platelets via P2Y1, P2Y12 or P2X1 receptors, and (5) is also 
metabolized into adenosine, which has anti-inflammatory protective effects. 
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Early proof of concept studies on ATP-liposomes pharmacological efficacy against 
cerebral ischemia were conducted on rats in the 1990’s. Liposomes efficiently protected ATP 
from plasma degradation, could cross the blood-brain-barrier under hypoxic conditions [24] 
and protected the rats against cerebral ischemic insults [7,23]. A closely related model of retinal 
ischemia [49] was later used to better understand the mechanism of action of these ATP-
liposomes. ATP delivery led to increased cell survival and decreased cell necrosis in primary 
retinal ganglion submitted to glucose-oxygen deprivation in vitro, and to decreased neurons 
death in the ganglion cell layer in vivo after ischemia-reperfusion. Pro-inflammatory genes were 
also down-regulated in ischemic retinas following ATP-liposomes treatment [25,26]. These 
simple ATP-liposomes were recently redesigned into pH-sensitive “energy formula”-loaded 
liposomes [46] (Figure 3B). The lipid composition was chosen in such a way that liposomes 
responded to pH and released their content at the penumbral intracellular pH. In addition, ATP 
was co-loaded with pentobarbital, which inhibits energy consumption, and with suramin, for 
blocking ATP toxic extracellular actions. Even though these liposomes protected a neuronal cell 
line against ATP depletion in vitro, they failed to protect astrocytes or endothelial cells under 
the same conditions and no in vivo data were reported. Hence, the superiority of these “energy-
formula”-liposomes, compared to simple ATP-liposomes, remains to be proven. 
ATP-liposomes were also shown to accumulate in myocardial infarct tissues in dogs [27]. 
Torchilin’s team confirmed this result in isolated rat hearts perfused with a Langendorff 
instrument and showed that ATP-liposomes could protect the mechanical functions of the 
myocardium during ischemia/reperfusion [29]. Similarly, ATP-liposome treatment reduced the 
fraction of the irreversibly damaged heart area within the total area at risk in a model of 
myocardium infarction in rabbits [28]. Further improvement of the liposomes was realized by 
functionalizing them with the monoclonal 2D4 antibody which specifically binds cardiac 
myosin [30] (Figure 3C). Intracellular cardiac myosin become, indeed, exposed to the blood-
stream after sarcolemmal disruption happening during ischemia. Hence, targeting these 
proteins should lead to higher accumulation of antibody-coated ATP-liposomes compared to 
bare ATP-liposomes. Even though this mechanism was not demonstrated in vivo, it was shown 
that the pharmacological efficacy of antibody-coated ATP-liposomes was enhanced compared 
to bare ATP-liposomes on isolated rat hearts perfused with a Langendorff instrument [31]. 
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Regarding liver ischemia, ATP liposomes have shown protective activity on rat models 
of both warm ischemia in vivo after a hypovolemic shock [32] and cold ischemia ex vivo during 
liver preservation for transplantation [33,34]. In both cases, authors witnessed an enhanced 
preservation of the ATP cellular content. Functionalizing ATP-liposomes with an 
asialoglycoprotein receptor ligand did not show any improved hepatocytes targeting or 
delivery efficacy so far [35], and their freeze-drying led to ATP leakage [36]. 
Regarding organ preservation, protective effects of ATP-liposomes were also tested on 
a model of ischemic pancreatic β cells for possible application on islet transplantation [37]. 
ATP-liposomes were functionalized with a fibronectin-mimetic peptide, which favored their 
cell internalization. Surprisingly, metabolic protection against the ischemic insult was shown 
to arise from both ATP and the lipids constituting the liposome (l,2-dipalmitoyl-sn-glycero-3-
phosphocholine (DPPC), cholesterol, PEG2000). However, ATP-liposomes could not restore 
insulin production from ischemic islet cells. 
Finally, in a model of mesenteric ischemia/reperfusion, authors showed that liposomal 
ATP could restore crypt proliferation but did not prevent cell death in the ischemic gut, arguing 
towards important complementary cytoprotective roles of other glucose metabolites like 
pyruvate [38]. 
Figure 3 Different types of ATP-liposomes. (A) Basic ATP-loaded liposomes can be complexified by 
(B) co-loading with complementary energy molecules like pentobarbital and suramin or (C) by 
functionalization with targeting moieties like antibodies or receptor ligands. The lipid bilayer 
composition can also be tuned to provide pH-sensitivity, fusogenicity or stealthiness. 
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In terms of commercial applications, highly fusogenic ATP-liposomes have been 
developed by the company Energy Delivery Solutions, a spin-off from Chien’s lab at the 
University of Louisville, under the product name of ATPv (formerly VitaSol). These liposomes 
are composed of a stable vesicle former, for example 1,2-dioleoyl-sn-glycero-3-phosphocholine 
(DOPC) or soy phosphatidylcholine (PC), and an unstable vesicle former, like 1,2-dioleoly-sn-
glycero-3-ethylphosphocholine (DOPC-e) or 1,2-dioleoyl-3-trimethyl-ammonium-propane 
(DOTAP) [50]. Dressings were saturated with these ATPv and applied to wounds to study the 
liposomes effect on skin healing. Very promising results were obtained on wounds performed 
on mice heads [41] and on ischemic ears of normal [42,45] or diabetic [44] rabbits. A very 
special finding was the discovery of a completely new healing process, with extremely fast 
granulation attributed to massive macrophage migration, their in situ proliferation and direct 
collagen production [42–45]. On a different therapeutic area, using a model of hemorrhagic 
shock on rats, these ATP-liposomes also improved survival when injected during resuscitation 
[39,40]. ATPv liposomes are currently sold as holding solutions for hair transplants. Clinical 
trials on other applications are eagerly awaited. 
In a completely different mindset, ATP-liposomes have also been used as a helper system 
for ATP-responsive nanocarriers. In this strategy, the delivery of an anticancer drug by 
fusogenic liposomes containing ATP-responsive DNA scaffold was enhanced by the co-
administration of ATP-liposomes [51]. 
All these studies show that there are still interesting perspectives in ATP-liposomes and 
ATP-vesicles development, particularly by tuning the cargo composition with other energetic 
molecules, by decorating the carrier surface with specific peptides or antibodies for enhanced 
targeting, and by finding new areas of applications. A better understanding of the ATP-
liposomes mechanism of action may help move this technology to the clinic. In particular, it 
would be interesting to confirm whether ATP-liposomes act only by delivering intracellular 
ATP or if this ATP delivery leads to adenosine extracellular delivery [52,53] as in the case of 
ADP-liposomes [48]. 
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II. Adenosine-lipid conjugates or nucleolipids 
Nucleolipids are composite molecules formed by the assembly of a lipidic component and a 
nucleobase, nucleoside or nucleotide.  
1) General synthetic strategies for adenosine nucleolipids 
Different chemical approaches can be employed to obtain artificial adenosine nucleolipids. A 
commonly employed strategy was first proposed by Shuto and colleagues in 1987 [54] for 
obtaining 5’-phosphatidyl-nucleosides (Figure 4A). This method’s popularity arises from its 
simplicity: a single-step enzymatic reaction in a two-phase system (chloroform and buffer) is 
necessary, in which phospholipase D catalyzes the transfer reaction of the phosphatidyl residue 
to the primary hydroxyl group of nucleosides. One of the first artificial adenosine nucleolipid, 
l,2-dipalmitoyl-sn-glycero-3-phosphatidyl-adenosine (DPPA), was synthetized by this method 
with a yield of 52 %. A few years later, Itojima et al. made use of this technique for creating a 
library of four 5’-phosphatidyl-adenosines with different alkyl chain lengths [55].  
Other organic strategies consist of activating either the adenosine monophosphate or 
the lipid moiety before coupling them. For example, 5’-phosphatidyl-adenosines can also be 
obtained by condensation of fatty alcohols with AMP activated by N,N'-
dicyclohexylcarbodiimide [10,56] or by reaction of AMP tetrabutylammonium salt with alkyl 
bromides [57]. Ahlers et al. created a new type of adenosine nucleolipids (Figure 4B, R’=H) by 
coupling N-hydroxysuccinimide actived esters of 2',3'-O-(3-carboxy-l-
methylpropyliden)adenosine [58] with mono or dialkylamines. More recently, Moreau et al. 
synthesized other types of adenosine nucleolipids (Figure 4B, R’=H) by reacting adenosine 
with dimethoxy ketal of palmitone [59]. These adenosine nucleolipids were also reacted with 
2-chloro-1,3,2-dioxaphospholane-2-oxide and trimethylamine in order to obtain lipid 
adenosine phosphocholines (Figure 4B, R’=phosphocholine) [59]. The same team also used 
imidazole activated fatty acids with 2’,3’-(isopropylidene)-5’-(phosphocholine)-adenosine to 
form lipid adenosine phosphocholines (Figure 4C, R’=phosphocholine) [60]. Over the same 
period of time, Couvreur’s team synthesized squalene-based adenosine conjugates [61,62] 
(Figure 4D).  
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A completely different strategy was recently introduced by Ceglie’s team using micellar 
catalysis. Practically, the 1,2-epoxydodecane was coupled to 5’-phosphoribonucleotide in an 
aqueous cationic microemulsion. The cationic interface favored the coupling between the water 
insoluble epoxide and the anionic nucleotides [63]. 
2) Adenosine nucleolipids self-assembly 
The attraction for nucleolipids in general (and adenosine nucleolipids in particular) has 
increased with the discovery of their capacity to form macro- or nanostructures. This unique 
property arises from both members of the couple: lipids have self-association ability and are 
known to organize in membrane layers and other structures such as liposomes, while 
nucleoside have base-pairing properties via hydrogen bonding or π-stacking.  
 Ahlers et al. were the first to explore this intriguing aspect. They compared single-chain 
or double-chain adenosine lipid monolayers and found that, to form stable structures, a balance 
had to be found between the lipophilicity procured by the alkyl chain and the size of the 
headgroup. Indeed, single-chain adenosine lipid did not form stable monolayers, while single-
Figure 4 Adenosine nucleolipids. R = lipids, R’ = H or phosphocholine. Lipids can be conjugated to 
adenosine by a phosphate diester link on the primary hydroxyl group of ribose to form 5’-phosphatidyl-
adenosines (A), attached to 2’,3’-hydroxyl groups of ribose through a ketal linkage (B) or ether bond (C), 
or coupled via an amide bond on the nucleobase (D). 
A B 
C D 
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chain adenine and double-chain adenosine did [58]. Some of these adenosine nucleolipids were 
even found to form various helical structures, with an impact of the alkyl chain length on the 
efficacy of the formation of these supramolecular assemblies [55]. It was also reported that the 
pH of the solution greatly affected the structure: as an example, 1,2-dimyristoyl-sn-glycero-3-
phosphatidyl-adenosine (DMPA) formed multihelical strands in alkaline conditions, while it 
formed tubular cigar-like scrolls in acidic conditions (Figure ).  
 
 
Since these early explorations, adenosine nucleolipids have been described to form 
many different structures including micelles and liposomes (Table 2), depending on the 
conjugated lipid and the buffer conditions.  
Figure 5 Electron micrograph of the formation process of cigar-like scrolls from DMPA in acidic solution 
(pH 5.0): (a) linear double-helical strand; (b) ribbon structure; (c) incomplete cigar-like scrolls from 
ribbon structure; (d) complete cigar-like scrolls. All scale bars represent 0.1 µm. Reprinted with 
permission from [55]. Copyright 1992 American Chemical Society. 
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Table 2 Adenosine nucleolipids and observed macrostructures. 
Chemical 
modification site 
Conjugate 
name 
Lipidic 
chains 
C:D Conjugated lipid Type of link Observed structures Reference 
5’-hydroxyl group 
of ribose 
AMPC16 1 16:0 
n-hexadecyl-
phosphorylcholine 
Phosphate 
diester 
Micelles [64,65] 
diC8PA 2 8:0 diC8PC 
Vesicles aging into double 
helical strands 
Quasi-spherical micelles 
[55,66–68]  
DDPA 2 10:0 DDPC 
Vesicles aging into double 
helical strands 
[55] 
DLPA 2 12:0 DLPC 
Long helicoidal micelles and 
wormlike structures 
[55,67,69,70] 
DMPA 2 14:0 DMPC Multihelical strands [55] 
POPA 2 
16:0 
18:1 
POPC Liposomes [71–74] 
DOP-Ade 2 18:1 DOPC Liposomes [71,75,76] 
2’,3’-hydroxyl 
groups of ribose 
 1  Octadecylamine 
Ketal 
 [58] 
 2  Dioctadecylamine Stable monolayers [58] 
 2  
N,N-dioctadecyl-l,3-
propanediamine  
Stable monolayers [58] 
PAPC 2 16:0 Palmitone 
Large lamellar structures 
Hydrogels 
[59,77] 
SAPC 2 18:0 Stearone 
Hydrogels 
Lamellar structures 
[77] 
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DOAPC 2 18:1 Oleyl fatty acids Ether 
Small unilamellar vesicles, 
worm-like structures and 
giant vesicles 
[60] 
6-amino group of 
adenosine 
SQAd 
1 25:5 
1,1’,2-trisnorsqualenic 
acid Amide Nanoparticles 
[61] 
1 30:6 squalenylacetic-acid [78] 
 
“C:D” represents the total amount of Carbon atoms versus the number of Double unsaturated bonds in the conjugated lipid chain. AMPC16: 
adenosine 5'-hexadecylphosphate; DDPA: 1,2-didecanoyl-sn-glycero-3-phosphatidyl-adenosine; DDPC: 1,2-didecanoyl-sn-glycero-3-
phosphocholine; diC8PA: 1,2-dioctanoyl-sn-glycero-3-phosphatidyl-adenosine; diC8PC: 1,2-dioctanoyl-sn-glycero-3-phosphocholine; DLPA: l,2-
dilauroyl-sn-glycero-3-phosphatidyl-adenosine; DLPC: l,2-dilauroyl-sn-glycero-3-phosphocholine; DMPA: 1,2-dimyristoyl-sn-glycero-3-
phosphatidyl-adenosine; DMPC: l,2-dimyristoyl-sn-glycero-3-phosphocholine; DOAPC: di-oleyl-adenosine-phosphocholine; DOP-Ade: 1,2-
dioleoyl-sn-glycero-3-phosphatidyl-adenosine; DOPC: 1,2-dioleoyl-sn-glycero-3-phosphocholine; PAPC: 2′,3′-O-16-hentriacontanyliden-
adenosine-5′-phosphocholine; POPA: 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphatidyl-adenosine; POPC: 1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphocholine; SAPC: 2’,3’-O-18-pentatriacontanyliden-adenosine-5’-phosphocholine; SQAd:  squalene-adenosine. 
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Compared to other nucleolipids, adenosine lipids possess some special properties. In 
addition to forming hydrogen bonds, adenosine, like other purines, has a high stacking 
tendency (Table 3), which leads to a negative Gibbs free energy for adenosine-adenosine 
association in aqueous solution [73]. These specificities affect several structural parameters of 
adenosine lipid self-assemblies, thus contributing to the final supramolecular structure. 
Table 3 Computed RNA nucleoside pairs stacking free energies [79] 
 
 
Indeed, when comparing l,2-dilauroyl-sn-glycero-3-phosphatidyl-adenosine (DLPA) and 
l,2-dilauroyl-sn-glycero-3-phosphatidyl-uridine (DLPU) wormlike aggregates, Bombelli et al. 
reported very different behaviors upon aging: while DLPU structures remained identical, DLPA 
aggregates self-assembled into giant twisted helicoidal aggregates [69]. The authors attributed 
this dissimilarity to higher association stacking constants of adenosine compared to uridine. 
This property also induced tighter nucleolipid arrangement in micelles in the case of 1,2-
dioctanoyl-sn-glycero-3-phosphatidyl-adenosine (diC8PA) compared to 1,2-dioctanoyl-sn-
glycero-3-phosphatidyl-uridine (diC8PU) [67]. Yet, this is not the case with all adenosine 
nucleolipids, as 2′,3′-O-16-hentriacontanyliden-adenosine-5′-phosphocholine (PAPC), for 
example, displayed a larger surface area per lipid compared to its equivalent 2′,3′-O-16-
hentriacontanyliden-uridine-5′-phosphocholine (PUPC) [80].  
Other phenomena attributed to adenosine high base-stacking potential were observed 
on several occasions by Baglioni’s team with 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphatidyl-
adenosine (POPA) structures. First, anhydrous POPA bilayers displayed a powder-like nature, 
which could be explained by a specific orientation of the stacked adenosine moieties, compared 
to 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphatidyl-uridine (POPU) [73] (Figure 6). Secondly, 
POPA/POPC (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine) bilayers exhibited the 
presence of POPA-enriched microdomains, due to partial demixing of POPA and POPC [81]. The 
adenosine stacking interactions responsible for this behavior could be detected by 
hypochromism [72]. Finally, POPA/POPC vesicles were found to be more stable than the 
equivalent POPG (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphatidyl-glycerol)/POPC, where the 
RNA nucleoside pair AA GG CC UU 
ΔGstack (kcal/mol) -2.41 -2.77 -1.76 -1.51 
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adenosine polar head was replaced by a glycerol head group bearing the same charge. 
According to the authors, only the base stacking interactions could explain this behavior [74].   
Mixing adenosine nucleolipids with uridine nucleolipids can also lead to original 
supramolecular architectures. Indeed, besides π-stacking, the presence of a nucleoside 
headgroup on a nucleolipid can also drive molecular recognition through hydrogen bonding 
with the complementary nucleoside on another nucleolipid. A very striking example of this 
phenomenon was presented by Moreau et al. by mixing PAPC and PUPC. While individual 
nucleolipids formed large lamellar structures, mixed nucleolipids self-assembled into small 
vesicles which could be visualized in real-time at the micrometer scale [59]. A similar 
phenomenon could be observed at the macroscopic scale between 2’,3’-O-18-
pentatriacontanyliden-adenosine-5’-phosphocholine (SAPC) and 2’,3’-O-18-
pentatriacontanyliden-uridine-5’-phosphocholine (SUPC): when separate, these two 
nucleolipids form hydrogels and fluid lamellar phases above a certain temperature. When 
mixed, however, they form a new stable combined supramolecular system, which forms a 
precipitate upon heating [77]. 
Figure 6 Geometrical minimization for a group of POPU (A) and POPA (B) molecules performed with 
Hyperchem 5.1 using AMBER force field. The orientation of purinic rings is strongly altered by the 
interaction between bases, whereas the pyrimidinic bases keep, more or less, their original 
conformation. Reprinted with permission from [73]. Copyright 2006 Elsevier. 
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3) Adenosine nucleolipids as delivery systems 
a. Adenosine nucleolipids lipoplexes for gene delivery 
As presented above, adenosine headgroups on nucleolipids can lead to molecular recognition 
with complimentary nucleolipids bearing uridine headgroups. Interestingly, this phenomenon 
of molecular recognition was also described between adenosine headgroups on nucleolipids 
and nucleic acids such as RNA or DNA. As a result, self-assembled adenosine nucleolipids may 
be considered as promising platforms for gene delivery [82]. A great advantage of this system 
is that it relies on specific Watson-Crick pairings (hydrogen bonding and π-stacking) between 
nucleolipids and polynucleotides, offering an interesting alternative to other non-viral 
technologies for gene deliveries which are based on aspecific electrostatic interactions [83].  
It was discovered by Baglioni’s team that when adenosine nucleolipid and polyuridilic 
acid (polyU) were brought together, the formation of nucleolipoplexes occurred without the 
presence of divalent cations (Figure 7). The proof-of-concept was obtained with diC8PA 
globular micelles decorated with single-stranded complimentary RNA: this association resulted 
in a polynucleotide-micelle adduct that could be characterized by SAXS as a hexagonal phase 
(Figure 7A) [84]. Other supramolecular structures were obtained with adenosine derivatives 
bearing a longer lipidic chain. Indeed, POPA bilayers swollen with a polyU-containing buffer 
exhibited an increase in their smectic period due to the appearance of a 1D lattice of 
polynucleotides between the POPA lamellar stacks (Figure 7B) [85]. The formation of these 
nucleolipoplexes was specific to the presence of adenosine as a functional headgroup leading 
to selective molecular recognition of nucleic acids. For example, POPG [72,74] and POPU were 
shown to be less able than POPA to associate with polynucleotides [86]. 
Despite these interesting observations, the in vitro and in vivo proofs of concept for using 
these nucleolipoplexes as gene delivery systems remain extremely limited. In particular, 
enhanced transfection efficacies at high lipid concentrations were obtained for two uridine 
nucleolipids compared to conventional lipid agents (DOTAP, TransFastTM and Lipofectamine® 
2000) [87,88], but so far, no study has been published regarding adenosine nucleolipids for 
gene delivery on pre-clinical models and no data are available in the literature regarding their 
transfection efficacy. 
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The most advanced study regarding the capacity of adenosine nucleolipid to deliver DNA 
inside cells was performed by Montis et al.. These authors investigated the adhesion and fusion 
processes of DNA-loaded POPA liposomes (formulated with POPC or 1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine – DOPE – helper lipids) with giant unilamellar vesicles (GUVs – 
composed of POPC or 1:1=POPC:POPG) used as a model of biological cell membranes. Both 
nucleolipoplexes and GUV membranes could be labeled with fluorescent probes and the 
interaction followed by laser scanning confocal microscopy and fluorescence correlation 
spectroscopy. It was observed that DNA-loaded POPA liposomes entered in contact with GUVs 
and fused, simultaneously delivering their DNA payload. Authors claimed that they were able 
to reproduce in vitro a recently highlighted possible non-endocytic internalization pathway 
happening in vivo for nucleic acid delivery, based on the fusion of lipoplex with the cell plasma 
membrane [89]. 
For gene delivery purpose, a different approach was imagined by Arteta et al.: instead of 
making use of the nucleolipid self-assembling properties, these authors non-covalently 
decorated poly(amidoamine) (PAMAM) dendrimers with l,2-dilauroyl-sn-glycero-3-
phosphatidyl-adenosine (DLPA) which has the ability to associate with nucleic acids. It is 
known that PAMAM dendrimers have the excellent ability to condense and translocate nucleic 
Figure 7 Nucleolipoplexes formed by interactions between adenosine nucleolipid derivatives and 
polyU. (A) Hypothetical arrangement of a hexagonal phase formed by polyU (red helixes) and cylindrical 
diC8PA micelles (green cylinders). Adapted with permission from [84]. Copyright 2007 John Wiley & 
Sons. (B) Hypothetical polyU arrangements between POPA membranes. Adapted with permission from 
[85]. Copyright 2007 American Chemical Society. 
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acids for gene delivery. However, this association is only driven by electrostatic interaction, 
which is not very specific and could happen with any other negatively charged surface or 
molecule. In addition, due to their positive charge, PAMAM dendrimers exhibited some toxicity. 
In that respect, as alternative, non-covalent association of anionic DLPA is a simple way of 
giving PAMAM dendrimers molecular recognition ability for specific association with nucleic 
acids [90]. 
As seen so far, this field of research tends to exclusively see adenosine nucleolipids as a 
new material for gene delivery. However, it seems to omit that adenosine itself is more than a 
polar head with base recognition ability and could be worth delivering for itself. 
b. Adenosine nucleolipids nanoparticles for adenosine delivery 
Other nucleolipids than adenosine ones are sometimes considered prodrugs, where the lipid 
moiety positively affects the drug biodistribution and leads to lowering toxicity and increasing 
pharmacological efficacy (e.g., anticancer or antiviral agents). Surprisingly, although adenosine 
is often acclaimed for its potential as therapeutic molecule whereas the  main limitation of this 
molecule lies in its hydrophilicity and short half-life in vivo, adenosine nucleolipids have rarely 
been considered with the aim of delivering adenosine itself [13,14].  
Squalene-adenosine (SQAd) is, to our knowledge, the only example of currently 
developed adenosine nucleolipid prodrug. The so-called “squalenoylation” technology consists 
in linking a derivative of squalene – a natural, biocompatible and biodegradable triterpene – to 
a hydrophilic active compound. The resulting bioconjugate showed the unique ability to self-
assemble into stable nanoparticles (NPs) [91].  
In the case of SQAd, two slightly different compounds were studied by Couvreur’s team: 
a SQAd bioconjugate with a short squalene-based chain constituted of 5 isoprene units [61] and 
a SQAd bioconjugate with a longer squalene-based chain constituted of 6 isoprene units [62]. 
Both compounds were found to self-assemble as NPs into an aqueous phase after 
nanoprecipitation (consisting in the addition of an ethanolic solution of SQAd into a water 
phase). The SQAd bioconjugate with 5 isoprene units was shown to form sponge-like 
macrostructures [61], while the SQAd with 6 isoprene units self-assembled into lamellar or 
hexagonal phase NPs, depending on the water-to-ethanol ratio during the nanoprecipitation 
process [92]. 
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The SQAd NPs with 6 isoprene units were used for in vivo pharmacological evaluation. 
Interestingly, the so-called “squalenoylation” of adenosine and its self-assembly into NPs 
dramatically affected adenosine pharmacokinetics and biodistribution in mice [93]. 
Importantly, adenosine plasma half-life was significantly increased after intravenous 
administration of SQAd NP, compared to adenosine injected free. Even though SQAd NPs did 
not show the ability to cross the blood-brain barrier, they displayed high neuroprotective 
pharmacological effect on cerebral ischemia in mice, as well as on spinal cord injury in rats [62]. 
Of note, free adenosine did not display any therapeutic activity in these models. Importantly, a 
complete toxicological study demonstrated the  perfect innocuity of SQAd NPs in mice [62]. 
Nevertheless, disposing of an easy-to-handle formulation would be a step further in the 
preclinical development of this system.  
On the other hand, the exact mechanism of action of SQAd NPs urgently deserves a 
deeper investigation, both at cellular and molecular levels. It was already shown that, after 
intravenous administration, the SQAd NPs disassembled before the bioconjugate inserted into 
low-density lipoproteins (LDLs), which explained the prolonged circulation time of SQAd in the 
blood [94]. The LDLs loaded with SQAd were further observed to be cell internalized through 
LDL receptor-dependent pathway [95]. But several questions remain: does the nanoparticle or 
SQAd bioconjugate itself act directly on adenosine receptors before internalization or is there 
a release in the extracellular space of free adenosine which bind to these receptors? If the 
second hypothesis is confirmed, how and where does this release happens? A better 
understanding would help to develop this promising technology further and extend its use to 
other therapeutic areas. 
  
  Introduction bibliographique  
37 
III. Conclusion 
Adenosine and lipids form a fertile couple with many different offspring. ATP-liposomes seem 
to be the most advanced technology in terms of clinical applications, even though they are far 
from being FDA-approved yet and they are only sold as cosmetics. Covalent conjugation 
between adenosine and lipids generated completely unexpected materials with self-assembly 
abilities, but they probably still need several years to mature as gene delivery systems. Use of 
these adenosine nucleolipids as adenosine delivery systems may be an elegant way of 
developing this technology faster towards clinical applications, as the example of squalene-
adenosine nanoparticles shows. 
Bringing nanomedicines into the clinic is generally challenging [96], especially because 
they are generally developed at the pre-clinical stage in academic laboratories and in an 
environment far from the conditions for the pharmaceutical development rules. Most works 
cited in this review lack a comprehensive approach, with a rigorous reflection on chemistry, 
manufacturing and controls as well as thorough in vitro and in vivo evaluation. Extremely basic 
characterization such as size, size distribution, surface characterization, drug loading and drug 
encapsulation are missing in most studies, while animal testing, when mentioned, generally 
focuses only on efficacy without describing detailed pharmacology and toxicology issues. 
Another difficulty comes from the fact that both adenosine and nanomedicines may be 
considered as risky bets from an industrial point of view. Indeed, the development of adenosine 
agonists and antagonists has often been synonymous with important clinical failures so far [97], 
creating some misgivings from investors, while the development of nanomedicines was still at 
an early stage some decades ago. However, as the first generation of nanomedicines has been 
successfully commercialized for more than 20 years now, industrials may become less reluctant 
to invest on these better-known technologies, under the condition that they can rely on solid 
preclinical studies. Hence, it is now time for them to fully exploit adenosine’s therapeutic 
potential.  
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Squalene-adenosine nanoparticles: 
ligands of adenosine receptors or 
adenosine prodrug? 
 
Abstract 
Adenosine receptors (ARs) represent key drug targets in many human pathologies, 
including cardiovascular, neurological and inflammatory diseases. To overcome the very 
rapid metabolization of adenosine, metabolically stable ARs agonists and antagonists 
were developed. However, few of these molecules have reached the market due to efficacy 
and safety issues. Conjugation of adenosine to squalene to form squalene-adenosine 
nanoparticles (SQAd NPs) dramatically improved the pharmacological efficacy of 
adenosine, especially for neuroprotection in stroke and spinal cord injury. However, the 
mechanism by which SQAd NPs displayed therapeutic activity remained totally unknown. 
In the present study, two hypotheses were discussed: (i) either SQAd bioconjugates, which 
constitute the NPs building blocks, act directly as ARs ligands, or (ii) adenosine, once 
released from intracellularly processed SQAd NPs, interacts with these receptors. The first 
hypothesis was rejected, using radioligand displacement assays, as no binding to human 
ARs was detected up to 100 µM of SQAd, in the presence of plasma. Hence, the second 
hypothesis was examined. SQAd NPs uptake by HepG2 cells, which was followed using 
radioactive and fluorescence tagging, was found to be independent of equilibrative 
nucleoside transporters but rather mediated by low-density lipoproteins receptors. 
Interestingly, it was observed that after cell internalization, SQAd NPs operated as an 
intracellular reservoir of adenosine, followed by a sustained release of the nucleoside in 
the extracellular medium. This resulted in a final paracrine-like activation of ARs pathway, 
evidenced by fluctuations of the second messenger cAMP. This deeper understanding of 
SQAd NPs mechanism of action provides now strong rational for extending the 
pharmaceutical use of this nanoformulation. 
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I. Introduction 
Adenosine is an endogenous purine acting on four different G protein-coupled receptors 
(GPCRs) identified as A1, A2A, A2B and A3. The wide distribution of these adenosine receptors 
(ARs) is associated with a great diversity of pathophysiological effects, including regulation of 
cardiovascular, nervous and immune systems (Fredholm et al., 2011). Although considerable 
efforts have been devoted to identifying new compounds interacting with ARs (Borea et al., 
2018), very few molecules have reached the clinic due to activity and/or toxicity issues. On the 
other hand, because of a very short half-life in the blood circulation (t1/2 ~ 10 s), adenosine must 
be administered at high doses which results in severe side effects, thus limiting the clinical use 
of this molecule. Therefore, innovative pharmaceutical strategies are still needed to fully exploit 
adenosine’s tremendous therapeutic potential. 
Currently, the so-called “squalenoylation” approach may represent a promising 
technological platform for delivering hydrophilic compounds with stability issues or off-target 
toxicity (Couvreur et al., 2006). This methodology consists of the conjugation of a fragile and 
quickly metabolized drug molecule to the squalene, a natural and biocompatible lipid. 
Interestingly, the resulting drug-squalene bioconjugates have the unique ability to self-
assemble in water as nanoparticles (NPs). It was found that these squalene-based NPs favorably 
modified the in vivo pharmacokinetics and biodistribution of the conjugated drug molecules 
(Reddy et al., 2007). In particular, the delivery of adenosine via squalene-adenosine (SQAd) NPs 
showed an impressive neuroprotective efficacy in brain ischemia in mice and in spinal cord 
injury in rats (Gaudin et al., 2014). This effect was explained by a prolonged circulation of SQAd 
NPs into the bloodstream compared to free adenosine (Gaudin et al., 2015), and appeared to 
originate from the interaction of SQAd NPs with the brain endothelial cells. However, the nature 
of the interaction between SQAd NPs and cells still remains totally unknown.  
 Thus, the current study aims at elucidating the mechanism of action of SQAd NPs in vitro. 
Two hypotheses were tested: (i) either the SQAd NPs or SQAd bioconjugates would act as direct 
ARs agonists (or antagonists) by binding them via their adenosine moiety; or (ii) they would 
function as prodrugs, by slowly releasing adenosine intracellularly and into the extracellular 
space. 
The first hypothesis was checked by radioligand displacement assays on membrane 
fractions of cells overexpressing human ARs. The second hypothesis was tested on the HepG2 
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cell line, a well-characterized in vitro human hepatocyte model. Liver cells were chosen for this 
study as it has previously been shown that SQAd NPs accumulate in high quantities in the liver 
after their intravenous injection in mice (Gaudin et al., 2015). The cell capture of SQAd NPs was 
followed by radiolabeling and fluorescent labeling, while adenosine release was determined by 
high-performance liquid chromatography (HPLC). Finally, the activation of the adenosine 
receptors was also evaluated. 
 
II. Materials and methods 
1) Materials 
SQAd bioconjugate originated from Holochem (Val-de-Reuil, France). D-(+)-glucose was 
obtained from Sigma (St Quentin Fallavier, France). Absolute ethanol and methanol came from 
VWR Chemicals (Strasbourg, France) while dimethyl sulfoxide was from Carlo Erba Reagents 
(Val-de-Reuil, France). MilliQ® water (resistivity 18.2 MΩ·cm) was purified on a system from 
Millipore (Molsheim, France). CholEsteryl 4,4-Difluoro-5,7-Dimethyl-4-Bora-3a,4a-Diaza-s-
Indacene-3-Dodecanoate (CholEsteryl BODIPY™ FL C12) and wheat germ agglutinin (WGA) 
Alexa FluorTM 555 conjugate were purchased from ThermoFisher Scientific (Karlsruhe, 
Germany). [2,8-3H]-Adenosine (specific activity 20.3 Ci/mmol) was obtained from Moravek 
Biochemicals (Brea, CA, USA) while SQ-[3H]-adenosine (SQ-[3H]-Ad) (specific activity 2.8 
Ci/mmol) was synthetized as previously reported (Gaudin et al., 2014). Soluene-350 and Hionic 
Fluor were provided by Perkin Elmer (Courtaboeuf, France). Radioligands 1,3-[3H]-dipropyl-8-
cyclopentylxanthine ([3H]DPCPX, specific activity of 120 Ci/mmol) and [2-3H]-4-(2-[7-amino-
2-{2-furyl}{1,2,4}triazolo{2,3-a}{1,3,5,}triazin-5-yl amino]ethyl)phenol ([3H]ZM241385, 
specific activity of 50 Ci/mmol) were purchased from ARC Inc. (St.Louis, MO). [3H]8-(4-(4-(4-
Chlorophenyl)piperazide-1-sulfonyl)phenyl)-1-propylxanthine ([3H]PSB603, specific activity 
79 Ci/mmol) and [3H]8-Ethyl-4-methyl-2-phenyl-(8R)-4,5,7,8-tetrahydro-1H-imidazo[2,1-i]-
purin-5-one ([3H]PSB11, specific activity 56 Ci/mmol) were kindly provided by Prof. C.E. Müller 
(University of Bonn, Germany). 5’-N-ethylcarboxamidoadenosine (NECA) was purchased from 
Sigma-Aldrich (Steinheim, Germany). N6‐cyclopentyladenosine (CPA) was purchased from 
Abcam (Cambridge, UK). Unlabelled ZM241385 was a gift from Dr. S. M. Poucher (Astra Zeneca, 
Macclesfield, UK). Adenosine deaminase (ADA) was purchased from Boehringer Mannheim 
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(Mannheim, Germany). Bicinchoninic acid (BCA) and BCA protein assay reagent were obtained 
from Pierce Chemical Company (Rockford, IL, USA). Chinese hamster ovary cells stably 
expressing the human A1, A2B or A3 ARs were provided by Prof. S. J. Hill (University of 
Nottingham, UK), Dr. S. Rees (AstraZeneca, Macclesfield, UK) and Dr. K-N. Klotz (University of 
Würzburg, Germany), respectively. HEK293 cells stably expressing the human A2A AR (HEK293 
hA2AAR) were kindly provided by Dr. J. Wang (Biogen/IDEC, Cambridge, MA, USA). hCMEC/D3 
cell line was a gift from Dr. Couraud (Hôpital Cochin, Paris, France). HepG2 cell line, Dulbecco’s 
Modified Eagle’s Medium (DMEM) high glucose, Dulbecco’s phosphate buffered saline (PBS), 
lipoprotein deficient serum (LPDS) from fetal calf, trypsin and penicillin-streptomycin, HEPES, 
hydrocortisone, basic fibroblast growth factor (bFGF), ascorbic acid, adenosine, cathepsin B 
from human liver, theophylline, dipyridamole, erythro-9-(2-hydroxy-3-nonyl)-adenine (EHNA) 
hydrochloride, paraformaldehyde, isobutyl-1-methylxanthine (IBMX) and 4-(3-butoxy-4-
methoxybenzyl) imidazolidone (Ro 20-1724) were obtained from Sigma (St Quentin Fallavier, 
France). Endothelial Basal Medium (EBM-2) medium was purchased from Lonza (Basel, 
Switzerland). GibcoTM fetal bovine serum (FBS) was obtained from Life Technologies (Saint-
Aubin, France).  
All other chemicals were of analytical grade and obtained from standard commercial 
sources. 
2) SQAd NPs preparation 
SQAd NPs were prepared as previously described (Gaudin et al., 2014). Briefly, 333 µL of an 
ethanolic solution of 6 mg/mL SQAd was added dropwise into 1 mL of a solution of 5 wt. % 
dextrose under stirring. Ethanol was then removed by evaporation using a Rotavapor® (Buchi, 
Rungis, France) to obtain a final concentration of 2 mg/mL SQAd NPs. Radiolabeled NPs were 
obtained following the same procedure, with the addition of SQ-[3H]-Ad to the ethanolic SQAd 
solution (final radioactivity 10 Ci/mol). Similarly, fluorescently labeled SQAd NPs were 
prepared by adding 40 µL CholEsteryl BODIPY FL C12 to the 333 µL ethanolic SQAd solution 
(the final concentration of fluorescent probe was 1 wt. %). Excitation and emission spectra 
were recorded using a LS 50B Luminescence Spectrometer (Perkin Elmer) (Supplementary 
Figure 1).  
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The mean NPs size and polydispersity index (PdI) were checked from 1 mg/mL 
suspensions by dynamic light scattering (DLS) using a Zetasizer Nano ZS (173° scattering angle, 
25 °C) (Malvern, UK). 
3) Radioligand displacement assay 
CHO or HEK293 cells stably expressing the human A1, A2A, A2B or A3 ARs were cultured and 
membranes were prepared as previously described (Heitman et al., 2009; Yang et al., 2017). 
Buffers compositions, membranes concentrations, radioligands and non-specific binding 
compounds used for each receptor type, as well as their concentrations, are listed in 
Supplementary Table 1. 
For radioligand displacement assays, membrane aliquots at given concentrations 
(Supplementary Table 1) were incubated in a total volume of 100 µL assay buffer 
(Supplementary Table 1) at 25 °C for 60 min (A1) to 120 min (other receptors). The dimethyl 
sulfoxide (DMSO) stock solution of SQAd as single bioconjugate molecules or the SQAd NPs 
preparation were diluted in assay buffer or FBS (DMSO final concentration < 1 %). Samples 
with serum were incubated for 4 h at 37 °C on an Eppendord Thermomixer before the 
experiment. Displacement experiments were performed in the presence of specific 
radioligands at given concentrations (Supplementary Table 1), while nonspecific binding was 
determined in the presence of non-specific binding compounds at given concentrations 
(Supplementary Table 1). Incubations were terminated by dilution with ice-cold assay buffer, 
immediately followed by separation of bound from free radioligand by rapid filtration through 
96-well GF/B filter plates using a Perkin Elmer Filtermate-harvester (PerkinElmer, Groningen, 
Netherlands). Filters were subsequently washed three times with 2 mL of ice-cold washing 
buffer (Supplementary Table 1). The filter-bound radioactivity was determined by 
scintillation spectrometry using a P-E 1450 Microbeta Wallac Trilux scintillation counter 
(PerkinElmer). IC50 values were obtained by fitting the curves with a one-site binding model 
using GraphPad Prism 7.00 software. Ki values were deduced using the Cheng-Prusoff equation 
(Cheng and Prusoff, 1973). 
4) Cell culture 
HepG2 cells were cultured in DMEM high glucose medium supplemented with 10 % FBS, 
penicillin (50 U/mL) and streptomycin (50 µg/mL). If not stated otherwise, cells were plated 
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on 24-well plates at a density of 200 000 cells per well and left to adhere overnight before any 
further procedure. 
hCMEC/D3 cells were cultured in EBM-2 medium supplemented with 5% FBS, penicillin 
(50 U/mL) and streptomycin (50 µg/mL), 1.4 μM hydrocortisone, 5 μg/mL ascorbic acid, 1% 
Chemically Defined Lipid Concentrate, 10 mM HEPES and 1 ng/mL bFGF. Cells were used 
between passages 4 and 8. Cells were plated on 24-well plates at a density of 100 000 cells per 
well and left to adhere overnight before any further procedure. 
All cells were maintained at 37 °C, 5 % CO2, 100 % humidity. Cells were passaged twice 
a week. 
5)  Cell uptake of radiolabeled SQAd NPs and free adenosine 
HepG2 cells were treated with radiolabeled SQAd NPs or radiolabeled free adenosine at a 
concentration of 10 µM and 0.1 µCi/mL. At different time points, cells were washed twice with 
PBS and detached with trypsin before been pelleted and resuspended in PBS. Samples 
radioactivity was measured using a β-scintillation counter (Beckman Coulter LS6500) after 
overnight incubation with 1 mL Soluene-350 at 50 °C and addition of 10 mL Hionic Fluor. 
6)  Cell uptake of fluorescently labeled SQAd NPs 
For confocal microscopy imaging, HepG2 cells were plated onto sterile glass coverslips placed 
in 24-well plates, at a density of 50 000 cells per well, and left to adhere for 48 h. Cells were 
incubated with fluorescently labeled SQAd NPs (10 µg/mL) for 2 h at 37 °C. After several 
washing steps with PBS, membranes were stained for 20 min with 10 µg/mL of WGA Alexa 
Fluor 555. Cells were then washed again and fixed with 4 % paraformaldehyde for 15 min. After 
final washing, coverslips were mounted on slides using Vectashield® mounting medium with 
4′,6-diamidino-2-phenylindole (DAPI) (Vector Labs) and sealed with nail polish. Images were 
acquired using a Leica TCS SP8 system, with a Leica HC Plan Apochromat 63×/1.4NO oil CS2 
objective lens.  
For studying the role of adenosine transporters, HepG2 cells were treated with 
fluorescently labeled SQAd NPs (10 µg/mL) and dipyridamole (20 µM). For studying the role of 
low-density lipoproteins receptors (LDLRs) in SQAd NPs cell uptake, 150 000 cells were plated 
by well. Cells were washed with PBS and medium was replaced with normal medium or 
Chapitre 1    
54 
medium supplemented with LPDS instead of FBS. Cells were then incubated for 24 h to enhance 
LDLRs expression, as proven by Western Blot (protocol from (Sobot et al., 2017a), 
Supplementary Figure 2) and subsequently treated with fluorescently labelled SQAd NPs (10 
µg/mL). In both cases, after 30 min or 2 h, cells were finally washed with PBS, detached with 
trypsin and resuspended in PBS. Cell fluorescence was evaluated using a BD AccuriTM C6 flow 
cytometer (BD Biosciences) with an excitation wavelength of 488 nm. Emission was recorded 
with the FL1 filter (533/30 nm). 
7)  SQAd degradation in acidic conditions 
A solution of 1 µL SQAd (2.5 mg/mL dissolved in DMSO) was incubated at 37 °C under shaking 
in 100 µL of 0.3 M sodium acetate buffer (pH 4.8) containing cathepsin B (10 U/mL). 
Degradation was stopped at different time points by the addition of 233 µL methanol. 5 µL 
gemcitabine-squalene (0.2 mg/mL dissolved in DMSO) were added as internal standard. 
Samples were centrifuged (14 000 rpm, 10 min) and resulting supernatants were evaporated 
to dryness at 37 °C under air flow. The dried samples were then dissolved in 100 µL of mobile 
phase (methanol for SQAd detection; methanol/KH2PO4 (10 mM, pH 4) 20/80 v/v, for 
adenosine detection) prior to HPLC analysis. 
8)  Adenosine extracellular release 
HepG2 or hCMEC/D3 cells were treated with SQAd NPs (100 µM), free adenosine dissolved in 
5 wt. % dextrose (100 µM) or 5 wt. % dextrose. After 5 min to 4 h, extracellular medium was 
replaced by 1 mL of simplified medium (composition is given in Supplementary Table 2) 
supplemented with 50 µM EHNA (to avoid adenosine deamination) and 2 µM internal standard 
(theophylline). After 5 min to 4 h, the extracellular medium was collected and extracted with 
2.3 mL of methanol. Samples were centrifuged at 17 000 x g for 10 min to remove insoluble 
materials and supernatants were filtered and evaporated to dryness at 37 °C under air flow. 
The dried samples were dissolved in 100 µL of mobile phase (methanol/KH2PO4 (10 mM pH 4) 
20/80 v/v) and filtered before HPLC analysis. The detection limit of the HPLC technique was 
17 nM for the adenosine, while the quantification limit was 55 nM. This method exhibited 
linearity (R2 = 0.99) over the assayed concentration range (100 - 1000 nM) and demonstrated 
good precision with relative standard deviation (RSD) being all less than 5%. 
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9)  HPLC conditions 
A Water™ 717 plus autosampler was employed equipped with a Waters™ 1525 binary HPLC 
pump, a Waters™ 2487 dual λ absorbance detector, and a Waters™ Breeze software. The 
analysis was performed using a Halo C18 column (4.6 x 250 mm, 5 µm; Interchim, France). The 
injection volume was 40 µL to 50 µL, the elution was carried out at 0.8 mL/min isocratically for 
10 min with the column temperature maintained at 30 °C. Detection wavelengths were 
respectively 273 nm for SQAd and 260 nm for adenosine. 
10) Intracellular cAMP levels 
The day before the experiment, two plates were seeded with HepG2 cells: a 24-well plate with 
200 000 cells per well and a 96-well plate with 5 000 cells per well. 
On the day of the experiment, cells in the 24-well plate were treated with SQAd NPs, free 
adenosine or dextrose as previously described. After 2 h, extracellular medium was replaced 
with simplified medium containing 50 µM EHNA and broad-range phosphatase inhibitors (500 
µM IBMX and 100 µM Ro 20-1724). After 1 h, 10 µL of this extracellular medium was used to 
stimulate cells plated in the 96-well plate for 15 min. cAMP intracellular levels were then 
determined using the cAMP-GloTM assay from Promega. Briefly, cells were lysed with 10 µL 
cAMP-Glo™ Lysis Buffer for 15 min with shaking at room temperature. cAMP-Glo™ Detection 
Solution and Kinase-Glo Reagent were then added to all wells according to the manufacturer's 
protocol. Luminescence was detected using an EnSpire Alpha 2390 plate reader (Perkin-Elmer, 
USA). 
 
III. Results 
1)  SQAd NPs 
Prepared by nanoprecipitation, SQAd NPs suspensions were monodisperse, displaying a 
hydrodynamic diameter of 71 ± 15 nm, a PdI of 0.08 ± 0.02 and a drug loading of 37%. 
Chapitre 1    
56 
2)  SQAd interaction with human adenosine receptors 
The direct interaction of SQAd with human ARs was checked by radioligand displacement 
assays. Specific radioligands were used for each adenosine receptor and their displacement was 
measured in the presence of increasing concentrations of SQAd bioconjugate or NPs. Results 
are shown in Figure 1 . 
Up to 1 µM, SQAd showed no interaction with any of the ARs in the assay buffer, whether 
as a bioconjugate or assembled as NPs (Figure 1 A and Figure 1 B respectively). At and above 
10 µM, some displacement became detectable, with both SQAd bioconjugates and NPs showing 
a slight preference for the adenosine A3 receptor (Figure 1 A and Figure 1 B). Using the Cheng-
Figure 1 Displacement of specific radioligands binding from the human adenosine receptors A1 (red 
circle), A2A (orange square), A2B (yellow triangle) and A3 (green diamond) by increasing concentrations 
of squalene-adenosine (SQAd) bioconjugate (A and C) or SQAd nanoparticles (NPs) (B and D) diluted 
in assay buffer (A and B) or preincubated for 4 h at 37 °C in fetal bovine serum (FBS) (C and D). 
Displacement experiments were performed at 25 °C. TB: total binding; NSB: non-specific binding. Data 
represent mean values ± standard deviation of three independent experiments. 
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Prusoff equation, the magnitude of SQAd (bioconjugate or NPs) affinity for each of these 
receptors was determined. Results are given in Table 1. 
 
Table 1 SQAd bioconjugate and SQAd NPs pKi magnitude for each adenosine receptor. 
 
 
The pKi values were determined from the radioligand displacement curves using the Cheng-Prusoff 
equation. 
 
To be as close as possible to the in vitro and in vivo conditions, SQAd bioconjugates and 
SQAd NPs were also preincubated for 4 h at 37 °C with FBS, prior to performing the radioligand 
displacement assay. It should be noted that the interaction with adenosine A2B receptor could 
not be evaluated under these conditions, due to unspecific interactions between the 
membranes and the FBS. Regarding the three other receptors, no interaction with SQAd 
bioconjugate or NPs could be detected anymore, even at the highest concentration (Figure 1 C 
and Figure 1 D). Hence, it was concluded that the preincubation with serum prevented 
interaction of SQAd with adenosine receptors.  
3) SQAd NPs internalization  
To follow the cell uptake of SQAd NPs, radiolabeled NPs were prepared by co-nanoprecipitation 
of SQAd and SQ-[3H]-Ad (for more information, see Materials and Methods section), with no 
influence of the radiolabeled compound on the NPs hydrodynamic diameter (56 ± 4 nm) or PdI 
(0.10 ± 0.04). HepG2 cells were then incubated at 37 °C for different times with either 
radiolabeled SQAd NPs or [3H]-adenosine. The resulting intracellular radioactivity is presented 
in Figure 2 Uptake of radiolabeled SQ-[3H]-adenosine (SQ-[3H]-Ad) NPs (red circle) or [3H]-
adenosine (orange square) by HepG2 cells (37 °C over 24 h). Data represent mean values ± 
standard deviation of two independent experiments..  
 pKi 
 A1 A2A A2B A3 
SQAd bioconjugate ≤ 4 < 5 ≤ 4 < 6 
SQAd NPs < 4 < 4 < 5 < 5 
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Both adenosine and SQAd NPs were internalized by HepG2 cells. However, the cell 
uptake of SQAd NPs occurred slower and to a lower extend than free adenosine. Indeed, after 
30 min incubation, the intracellular content in adenosine (and its tritiated metabolites) was 13-
times higher than with SQAd (and its metabolites). After 24 h, however, the adenosine over 
SQAd ratio was reduced to a value of only 3.  
 
For further experiments, fluorescently labeled SQAd NPs (diameter of 60.8 ± 0.4 nm, PdI 
of 0.13 ± 0.01) were prepared by co-nanoprecipitation of SQAd with a fluorescent BODIPY-
cholesteryl ester dye. Fluorescent nanoparticles maximum excitation and emission 
wavelengths were respectively of 484 nm and 520 nm (Supplementary Figure 1). NPs uptake 
by HepG2 cells was visualized by confocal microscopy and measured by flow cytometry under 
various conditions (Figure 3 ). The fluorescently labeled SQAd NPs were found to be taken up 
by HepG2 cells (2h incubation) (Figure 3 A), while no fluorescence was visible when the cells 
were incubated with the fluorescent probe alone (Figure 3 B). Hence, the intracellular 
fluorescence was considered to correlate well with SQAd NPs uptake.  
Then, considering that adenosine enters the cells via equilibrative nucleoside 
transporters (ENTs) (Baldwin et al., 2004), the cellular mechanism of uptake of SQAd NPs was 
also investigated using HepG2 cells treated with dipyridamole, an ENT inhibitor. After 30 min 
or 2 h of incubation with fluorescently labeled NPs, no difference in intracellular fluorescence 
was observed between cells pre-incubated with or without dipyridamole (Figure 3 C), which 
clearly indicated that SQAd NPs did not enter the cells via ENTs.  
Figure 2 Uptake of radiolabeled SQ-[3H]-
adenosine (SQ-[3H]-Ad) NPs (red circle) or [3H]-
adenosine (orange square) by HepG2 cells (37 °C 
over 24 h). Data represent mean values ± 
standard deviation of two independent 
experiments. 
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The role of LDLRs was then evaluated by tuning their level of expression on HepG2 cells. 
Cells were preincubated for 24 h with FBS-supplemented medium (containing normal level of 
lipoproteins), and LPDS-supplemented medium (containing low levels of lipoproteins). Cell 
starvation using LPDS induced an over-expression of LDLRs, as evident from Western Blot 
(Supplementary Figure 2). Noteworthy, in LPDS-supplemented medium, cells were found to 
internalize higher levels of fluorescently labeled SQAd NPs (Figure 3 D), thus demonstrating 
an influence of LDLRs expression level on SQAd NPs uptake.  
Figure 3 Cell uptake of fluorescently labeled SQAd NPs by HepG2 cells. (A, B) Confocal microscopy 
images of HepG2 cells incubated for 2 h with (A) fluorescently labeled SQAd NPs or (B) the fluorescent 
tag BODIPY-cholesteryl ester dye as a control, prepared under the same conditions as NPs. Cell 
membranes were stained with wheat germ agglutinin Alexa Fluor 555 (red) while DAPI was used to 
visualize nuclei (blue). Scale bar = 50 µm. (C, D) Relative fluorescence measured by flow cytometry 
from HepG2 cells incubated for 30 min or 2 h with fluorescently labeled SQAd NPs. (C) Cells treated 
with NPs were incubated in the absence (bright red bars) or in the presence (dark red bars) of 
dipyridamole (dipy). (D) Cells were preincubated for 24 h with FBS-supplemented (bright red bars) 
or LPDS-supplemented DMEM (pink bars). Cell auto-fluorescence was subtracted from each data set. 
Data represent mean values ± standard deviation of three independent experiments. ** indicates p < 
0.01, two-way ANOVA with Tukey’s post hoc test. 
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4)  SQAd degradation in acidic conditions 
Assuming that once in the cell, SQAd would undergo hydrolysis in acidic endo-lysosomal 
compartments, SQAd degradation was then evaluated over 24 h in acidic conditions (pH 4.8) in 
the presence or in the absence of cathepsin B, a typical lysosomal enzyme able to cleave amide 
bonds. The percentage of intact prodrug under these conditions is shown in Figure 4 A. 
Although almost no bioconversion of the SQAd bioconjugate could be observed until 6 h, 
up to 20 % of SQAd was degraded after 24 h of incubation in acidic conditions. The presence of 
cathepsin B did not influence the degradation profile over 24 h. Interestingly, the degradation 
of SQAd led to the release of free adenosine (retention time 3.9 min), which was characterized 
by HPLC analysis (Figure 4 B). 
Hence, SQAd intracellular bioconversion into adenosine should increase the adenosine 
intracellular content. And, as a result of the equilibrium between the intracellular and the 
extracellular adenosine levels, it was hypothesized that some adenosine could be further 
released in the extracellular compartment. 
5)  Adenosine extracellular release 
Thus, the concentration of adenosine released in the cell culture medium was then determined 
by HPLC in the presence of EHNA, an inhibitor of adenosine deaminase. After incubation of 
Figure 4 (A) Percentage of intact SQAd after incubation until 24 h, with or without cathepsin B (pH 4.8, 
37 °C). Data represent mean values ± standard deviation of two independent experiments. (B) 
Representative HPLC chromatogram of partial activation of SQAd into adenosine (Ad) (24 h incubation, 
pH 4.8, 37 °C, in the presence of cathepsin B). Of note, the peak corresponding to SQAd is not visible in 
the elution conditions used for adenosine detection. AU: arbitrary unit. 
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HepG2 (or hCMEC/D3) cells with SQAd NPs, free adenosine or 5 % dextrose solution, the 
extracellular medium was replaced by 1 mL of a new simplified medium (composition is given 
in Supplementary Table 2) to remove adenosine (eventually resulting from the release from 
SQAd NPs before their capture by the cells). After further 5 min to 4 h incubation, the 
extracellular medium was finally collected to determine the quantity of adenosine released 
from the cells after exposure to SQAd NPs or adenosine (Figure 5A). 
After 5 min incubation, cells treated with free adenosine released higher concentrations 
of adenosine (around 600 nM) than cells treated with dextrose or SQAd NPs (100 nM to 200 
nM). This clearly highlighted the almost instantaneous ability of the cells to uptake free 
adenosine, while SQAd NPs uptake and cleavage (which results in adenosine metabolite release) 
required more time (Figure 5A). Interestingly, after longer incubation time with free adenosine, 
a decrease in adenosine release was observed, which likely resulted from a consumption of the 
overall pool of adenosine by the cells. On the contrary, after longer incubation time with SQAd 
NPs, higher levels of released adenosine were observed, which correlated well with an 
increased intracellular content of SQAd over time, hence producing a reservoir effect. Of note, 
very close results were obtained with hCMEC/D3 cells, a brain endothelial cell line derived from 
human temporal lobe microvessels (Supplementary Figure 3).  
Figure 5 Concentrations of adenosine released in the extracellular medium from HepG2 cells exposed 
to various treatments. (A) Cells were incubated for indicated times with 100 µM of SQAd NPs (red bars), 
adenosine (Ad) (orange bars) or 5 wt. % dextrose (yellow bars) and released adenosine concentrations 
were measured 1 h following cell culture medium renewal. (B) Cells were incubated for 2 h with 100 µM 
of SQAd NPs (red circles), adenosine (Ad) (orange squares) or 5 wt. % dextrose (yellow triangles) and 
released adenosine concentrations were measured at different times. Data represent mean values ± 
standard deviation of three (A) or two (B) independent experiments. 
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To further study the intracellular reservoir effect of adenosine produced after 
incubation with SQAd NPs, cells were incubated for 2 h with free adenosine, SQAd NPs or 
dextrose and the kinetics of adenosine release from the cells into the extracellular medium was 
determined. Results are shown in Figure 5B. Interestingly, concentrations of released 
adenosine after incubation of the cells with dextrose or free adenosine did not increase over 
time, thus revealing that equilibrium was reached during the first minutes post incubation. On 
the contrary, when the cells were incubated with SQAd NPs, quantities of adenosine released 
by the cells increased over time. This clearly confirmed the reservoir effect resulting from the 
intracellular accumulation of SQAd NPs followed by the progressive cleavage of the SQAd 
bioconjugate, allowing a progressive release of free adenosine in the extracellular medium. 
A remaining question was to know whether the released adenosine in the extracellular 
medium was capable of interaction with adenosine receptors on neighboring cells. 
6)  Adenosine receptors activation 
Thus, adenosine receptors activation was evaluated by measuring the levels of intracellular 
cAMP. Indeed, adenosine receptors are G protein-coupled receptors (GPCR) known to activate 
or inhibit adenylate cyclase, hence tuning intracellular levels of cAMP. As in the previous set of 
experiments, HepG2 cells were incubated with dextrose, free adenosine or SQAd NPs for 2 h 
and then allowed to release adenosine during 1 h in their extracellular medium. This medium 
was then used as adenosine pool to investigate the interaction, through 15 min incubation, with 
other naïve cells by measuring their intracellular cAMP levels. As can be seen in Figure 6, the 
extracellular medium originating from cells treated with control vehicle (5 wt. % dextrose) or 
free adenosine did not induce major changes in intracellular cAMP levels. However, 
extracellular medium arising from cells treated with SQAd NPs induced a significant increase 
in cAMP, comparatively to vehicle. Interestingly, adenosine levels in extracellular medium 
originating from cells treated with SQAd NPs or free adenosine were very close under the 
conditions used (2 h of treatment and 1 h of release, cf. Figure 5A). Hence, adenosine might not 
be the only factor in the extracellular medium interacting with GPCRs. 
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IV. Discussion 
This study aimed at clarifying the mechanism of action of SQAd NPs in vitro. The main question 
was to determine whether SQAd acted directly on ARs as a specific ligand, or indirectly as a 
prodrug releasing active adenosine. 
By using radioligand displacement experiments, it was measured that SQAd as 
bioconjugate or as NPs displayed a rather weak affinity for human ARs, showing Ki superior to 
10-6 M for A3 and to 10-5 M for all other ARs. As a matter of comparison, the native ligand 
adenosine has an affinity of around 10-7 M for A1, A2A and A3 and 10-6 M for A2B (Yan et al., 2003).  
More importantly, when SQAd bioconjugate or NPs were preincubated in serum to 
mimic the in vivo conditions, no more binding onto ARs could be detected. This was attributed 
to the interaction of SQAd with plasma proteins, especially with cholesterol-rich lipoproteins, 
i.e. low-density lipoproteins (LDLs) in humans and high density lipoproteins in rodents (Sobot 
et al., 2017b). In silico simulations have confirmed that the interaction of the squalene-based 
bioconjugates with the LDL was driven by the squalene moiety, allowing the hydrophilic 
adenosine to insert deeply into the LDL hydrophobic core (Yesylevskyy et al., 2018). Thus, 
LDLs may hinder the possible interaction of SQAd with ARs. As a result, the hypothesis that 
SQAd may act directly on ARs as a ligand could be rejected.  
In order to assess the second hypothesis related to the progressive release of adenosine 
from SQAd NPs after cell capture, cultured hepatocytes were used. HepG2 cell line was chosen 
because SQAd NPs concentrated into the liver tissue after intravenous administration (Gaudin 
et al., 2015).  
Figure 6 Changes in intracellular cAMP levels of naïve cells 
incubated during 15 min with extracellular medium 
collected from other cells exposed to SQAd NPs, free 
adenosine (Ad) or 5 wt. % dextrose (Dext). Changes in 
relative luminescence units (ΔRLU) were calculated as the 
difference in light units between treated and untreated 
cells. Data represent mean values ± standard deviation of 
three independent experiments. ** indicates p < 0.01, one-
way ANOVA with Tukey’s post hoc test. 
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It was observed that the cell capture of SQAd NPs was independent from the ENTs 
adenosine transporters. And as ENTs selectively mediate the bidirectional transport of 
nucleosides, nucleobases and nucleoside analogs (Boswell-Casteel and Hays, 2017), the 
presence of the squalene bulky moiety in SQAd was supposed to prevent the interaction of the 
adenosine fragment with ENTs. By contrast, the cell internalization of SQAd NPs was found to 
occur through the LDLRs.  
As LDLRs are known to trigger the cell internalization via clathrin-dependent 
endocytosis (Goldstein et al., 1985), it was quite likely that SQAd followed the same pathway, 
thus ending up in endosomes and then lysosomes. This hypothesis is in perfect agreement with 
the confocal microscopy images obtained in this study (Figure 3 A). Once in the lysosomes, 
SQAd underwent a slow degradation under acidic conditions. Even though cathepsin B alone 
did not accelerate this proteolytic degradation under tested conditions, its combination with 
other enzymes like cathepsin D (Couvreur et al., 2006) and proteases may accelerate this 
phenomenon in vitro and in vivo. In addition, it was observed that the intracellular cleavage of 
SQAd into free adenosine resulted also in an extracellular release of adenosine, which gradually 
increased over time. In other words, SQAd behave as an intracellular reservoir, slowly releasing 
adenosine in the extracellular medium, probably via ENTs, since these transporters could act 
bidirectionally. Interestingly, the human brain endothelial hCMEC/D3 cell line showed similar 
adenosine extracellular release after SQAd NPs internalization which suggests that the 
interaction of SQAd NPs with HepG2 cells represents a more general trend occurring also in 
other cell types. 
Finally, higher cAMP second messenger levels were observed in cells incubated with the 
extracellular medium originating from cells treated with SQAd NPs, which clearly indicated an 
increased activation of ARs. But since adenosine levels in the extracellular medium originating 
from cells treated with SQAd NPs or free adenosine were very close under the conditions used, 
adenosine might not be the only factor in the extracellular medium interacting with GPCRs.  
In a nutshell, this study led to a better understanding of SQAd NPs mechanism of action 
as illustrated in Figure 7. Unlike currently proposed agonists and antagonists of ARs, SQAd NPs 
do not interact directly with the ARs but function in a very original way, as a prodrug delivering 
high quantities of adenosine into the cells. Hence, cells dispose of an important intracellular 
reservoir of adenosine, progressively releasing the nucleoside which, in turn, can act as an 
autocrine or paracrine factor. In conclusion, SQAd NPs provide an efficient system for 
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prolonged adenosine delivery resulting in AR activation. This new delivery pathway may open 
interesting prospects in terms of clinical applications. 
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VI. Supplementary materials 
 
 
Supplementary Table 1 Buffer composition, membrane final concentration, radioligand and unlabeled 
ligands name and concentrations used for each type of receptor. BSA: bovine serum albumin; CHAPS: 3-
[(3-cholamidopropyl) dimethylammonio]-1-propanesulfonate; EDTA: ethylenediaminetetraacetic acid; 
NSB: non-specific binding. 
  
Receptor A1 A2A A2B A3 
Assay buffer 
50mM Tris, pH 7.4 
50mM Tris-HCl, 
0.1% CHAPS, pH 
7.4 
50mM Tris, 10mM 
MgCl2, 1mM EDTA, 
0.01% CHAPS, pH 8.0 
Washing buffer 
50mM Tris-HCl, 
0.1% BSA, pH 7.4 
50mM Tris, 10mM 
MgCl2, 1mM EDTA, pH 
8.0 
Membrane 
concentration 
(µg/mL) 
50 200 250 150 
Radioligand  [3H]DPCPX  [3H]ZM241385 [3H]PSB603 [3H]PSB11 
Radioligand 
concentration (nM) 
1.6 2.5 1.5 10 
NSB compound  CPA NECA ZM241385 NECA 
NSB compound 
concentration ( µM) 
100 100 10 100 
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Simplified media composition Concentration (g/L) 
Compound HepG2 hCMEC/D3 
D-(+)-Glucose 4.5 5.5 
CaCl2 0.2 0.1776 
Fe(NO3)3 0.0001  
FeSO4 0.0002  
MgSO4 0.09767 1.2037 
KCl 0.4 0.2982 
NaHCO3 3.7 1.1761 
NaCl 6.4 6.1362 
NAH2PO4 0.109 0.0710 
 
Supplementary Table 2 Simplified cell culture media formulation. This composition corresponds to 
the sugars and inorganic salts contents of the cell culture media used for daily cell culture, neglecting 
other compounds like vitamins and amino acids. 
 
  
Supplementary Figure 1 
Fluorescently labeled SQAd NPs 
excitation and emission spectra. For 
excitation spectra, emission was 
recorded at λem = 520 nm, while for 
emission spectra, NPs were excited 
at λexc = 485 nm. 
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Supplementary Figure 2 LDLR expression by HepG2 cells cultured for 24 h in FBS-supplemented 
medium (1-2) or in LPDS-supplemented medium (3-4). Protein equivalent loading in each well was 
demonstrated by probing for β-actin (42 kDa). LDLR are visible at the predicted band size (95 kDa) 
and at a higher size (140 kDa), which corresponds to the glycosylated form of the protein, as indicated 
by the manufacturer. 
Supplementary Figure 3 Concentrations of adenosine in the extracellular medium from hCMEC/D3 
cells cultures. Cells were incubated for indicated times with 100 µM of SQAd NPs (red bars), adenosine 
(Ad) (orange bars) or 5 wt. % dextrose (yellow bars) and released adenosine concentrations were 
measured 1 h following cell culture medium renewal. 
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Towards a clinical application of freeze-
dried squalene-based nanomedicines 
 
Abstract 
As many other nanomedicines, squalene-adenosine (SQAd) nanoparticles (NPs) were 
found to display promising pharmacological activity, but their long-term stability was still 
limited, and their preparation required specific know-how and material. These drawbacks 
represented important restrictions for their potential use in the clinic. Freeze-drying 
nanoparticles is commonly presented as a solution to allow colloidal stability, but this 
process needs to be adapted to each nanoformulation. Hence, we aimed at developing a 
specific protocol for freeze-drying SQAd NPs while preserving their structural features. 
NPs were lyophilized, resuspended and analysed by dynamic light scattering, atomic force 
microscopy and small-angle scattering. Among four different cryoprotectants, trehalose 
was found to be the most efficient in preserving NPs physico-chemical characteristics. 
Interestingly, we identified residual ethanol in NPs suspensions as a key parameter which 
could severely affect freeze-drying outcome, leading to NPs aggregation. Long-term 
stability was also assessed. No significant change in size distribution or zeta potential 
could be detected after three-month storage at 4 °C. Finally, freeze-dried NPs innocuity 
was checked in vitro on cultured hepatocytes and in vivo on mice. In conclusion, 
optimisation of freeze-drying conditions resulted in safe lyophilized SQAd NPs that can be 
easily stored, shipped, and simply reconstituted into an injectable form. 
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I. Introduction 
Adenosine is a ubiquitous purine nucleoside which is essential for cell metabolism. It plays 
many important biological roles intra and extracellularly. On one hand, intracellular adenosine 
is involved in nucleic acid and energy metabolism, as a major component of ATP. On the other 
hand, extracellular adenosine acts as a key intercellular signal by binding four widely expressed 
G-protein-coupled receptors: A1, A2A, A2B and A3. The pharmacological effects of adenosine are 
well recognized in diverse physiological functions including neurological, cardiovascular and 
immunological, as well as in pathological situations like inflammation, pain or cancer (1, 2). In 
that respect, adenosine is sometimes described as a “multi-signalling guardian angel” (3).  
However, the clinical use of adenosine has been hindered by its very-short plasmatic 
half-life (< 10 s). Considerable efforts have been devoted to therapeutically target adenosine 
signalling with stable agonists or antagonists but serious challenges remain, mostly due to the 
severe side effects observed after the systemic administration of these compounds (4, 5). 
Innovative drug delivery techniques offer a promising strategy for protecting adenosine 
from rapid metabolization and sustaining its release (6). The most promising strategy in terms 
of in vivo efficacy consists in conjugating adenosine to squalene (7), a human endogenous lipid. 
This process results in the formation of an amphiphilic prodrug which can self-assemble into 
NPs in aqueous solutions after nanoprecipitation. These squalene-based NPs favourably 
modified the pharmacokinetic profile and biodistribution of adenosine (8), leading to dramatic 
neuroprotective effects on cerebral ischemia and spinal cord injury after intravenous 
administration, without producing any side effect (7).  
If these impressive preclinical results suggest attractive prospects in clinical 
development, major obstacles remain. Squalene-adenosine (SQAd) NPs are formulated as liquid 
suspensions, which do not match industrial requirements in terms of transport and 
conservation. Indeed, NPs displayed a limited colloidal long-term stability, with NPs 
aggregation or fusion. In addition, nanoprecipitation requires appropriate equipment and 
know-how, restraining their direct preparation before administration. 
Lyophilization is a common way to overcome these limitations prior to pharmaceutical 
distribution. The main goal of this method is to obtain a solid-state product as a “soft cake’’ 
which can be easily redispersed when required. Such preparation has numerous advantages 
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including easier manipulation, usually increased solubility in water and increased shelf-life of 
the product (9). This industrial process, also called lyophilization, consists in removing all 
water (or solvent) from a frozen suspension by sublimation under low pressure. But NPs will 
face several types of stress during freezing and dehydration, among which an increase in 
solutes local concentrations as pure water forms ice blocks and sublimes, and a mechanical 
stress due to ice crystallization and reduced pressure. The addition of cryo- and lyoprotectants 
(mainly sugars) usually protect NPs from these stresses by vitrifying the solution (10). However, 
surprisingly, the influence of freeze-drying on the NPs supramolecular organization, which may 
(11) or may not (12) be affected by removal of structural water, has rarely been discussed. 
Thus, the present study aimed at investigating the physical, analytical and structural 
characterization of SQAd NPs prior and after lyophilization. The cryoprotective activity of four 
carbohydrates (dextrose, sucrose, trehalose and mannitol) at different concentrations was 
evaluated using dynamic light scattering techniques allowing to determine the mean particle 
size and size distribution before and after freeze-thawing. Best conditions were then used for 
freeze-drying the NPs. The influence of residual ethanol on the freeze-drying successful 
outcome was also studied. In order to evaluate NPs chemical and structural integrity, 
lyophilized samples were characterized respectively by nuclear magnetic resonance (NMR), 
atomic force microscopy (AFM) and small angle scattering. Furthermore, the long-term stability 
of the dried samples was evaluated after storage for up to three months. Finally, absence of 
toxicity after freeze-drying was checked in vitro on hepatocytes, as well as in vivo on mice. 
 
II. Materials and methods 
1) Materials 
SQAd bioconjugate was provided by Holochem (Val-de-Reuil, France). D-(+)-glucose (≥ 99.5%), 
D-mannitol (≥ 98%), D-(+)-trehalose dihydrate (from Saccharomyces cerevisiae, ≥ 99%), 
sucrose (≥ 99.5%) and thiazolyl blue tetrazolium bromide (MTT) were purchased from Sigma-
Aldrich (Saint-Quentin-Fallavier, France). Absolute ethanol (≥ 99.8%) originates from VWR 
Chemicals (Fontenay-sous-Bois, France). MilliQ® water (resistivity 18.2 MΩ·cm) was produced 
by a water purification system (Millipore, Molsheim, France). Deuterium oxide (D2O) and 
  Chapitre 2  
75 
chloroform-d (CDCl3) were supplied by Euriso-top (Saint-Aubin, France). Pall® Acrodisc® glass 
fibre syringe filters (diameter 25 mm, pore size 1 μm) and Minisart Syringe filters (pore size 
0.2 μm) were respectively purchased from Sigma-Aldrich (Saint-Quentin-Fallavier, France) and 
Sartorius (Dourdan, France). HepG2 cell line, Dulbecco’s Modified Eagle’s Medium (DMEM) 
high glucose, Dulbecco’s phosphate buffered saline (DPBS), trypsin and penicillin-streptomycin 
were obtained from Sigma (Saint-Quentin-Fallavier, France). GibcoTM foetal bovine serum (FBS) 
was obtained from Life Technologies (Saint-Aubin, France). 
2) SQAd NPs preparation 
SQAd NPs were prepared by the nanoprecipitation method. Briefly, the SQAd bioconjugate was 
dissolved into pure ethanol (6 mg/mL) and 333 µL of this solution was added dropwise into 1 
mL of water solution under stirring (500 rpm). The solution became spontaneously turbid with 
a slight Tyndall effect, indicating the formation of the nanoparticles. The total mass mi was 
evaluated. Ethanol was evaporated with a Rotavapor® R-215 (Buchi, Switzerland): the pressure 
was slowly decreased to 43 mbar and the flask was immersed into the water-bath at 40 °C. The 
mass mf remaining in the flask after evaporation was evaluated and water was added to reach 
a final volume of 1 mL (considering a density of 1) and a concentration of 2 mg/mL.  
The percentage of evaporation %𝐸𝑣𝑎𝑝 was defined as: 
%𝐸𝑣𝑎𝑝 =
𝑚𝑖 − 𝑚𝑓
𝑚𝑖
× 100. 
If not stated, evaporation was over 50 %. 
3) Dynamic light scattering (DLS) 
The mean NPs size, polydispersity index (PdI) and zeta potential were evaluated from 1 mg/mL 
suspensions by DLS using a Zetasizer Nano ZS (173° scattering angle, 25 °C) (Malvern, UK). The 
measurements were performed in triplicate: size measurements consisted in 1 run of 60 s each, 
while zeta potential measurements were recorded in automatic mode. Due to limited 
information in the literature regarding carbohydrates solutions viscosities and refractive 
indexes at 25 °C, water values were used for all measurements. Hence, apparent size and zeta 
potential are reported. 
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4) Freeze-thawing and freeze-drying experiments 
NPs suspensions were mixed with 0.2 µm-filtered 10 wt. % carbohydrates solutions and water 
to obtain a final NPs concentration of 1 mg/mL and concentrations of sugars ranging from 0.5 
wt. % to 5 wt. %. Thus, 500 μL were placed in 1.5 mL Eppendorf tubes and then frozen in a 
freezer (-30 °C, 24 h) or liquid nitrogen (-196 °C, 10 min). For freeze-thawing experiments, NPs 
were directly thawed after freezing step. For freeze-drying experiments, NPs were then dried 
overnight in an Alpha 2-4 LD plus freeze-dryer (Martin Christ Gefriertrocknungsanlagen GmbH, 
Germany) (condenser < 70 °C, vacuum < 0.1 mbar). After lyophilization, samples were 
reconstituted by the addition of 500 µL MilliQ water and gently homogenized by pipetting. 
Osmolality was measured by the freezing-point depression method on a micro-osmometer 
Autocal Type 13 (Roebling). For NMR analysis, SQAd was extracted from the lyophilisate using 
chloroform-d, and a drop of D2O was then added in the sample prior to analysis. 1H spectrum 
was recorded on a Bruker Avance-300 spectrometer at 300 MHz. 
5) Quantitative determination of residual ethanol 
NPs suspensions were centrifuged (16,873 x g, 1 h, 4 °C). Ethanol concentrations (vol. %) in the 
supernatant were measured with the QuantiChromTM Ethanol Assay Kit (BioAssay Systems, CA, 
USA), according to the manufacturer instructions. Absorbance at 570 nm was corrected with 
background absorbance at 650 nm. 
6) Quantitative determination of residual moisture 
Residual moisture was determined by the loss-on-drying technique. Briefly, clean annotated 
empty Eppendorf tubes were dried for over 30 min at 60 °C under vacuum (< 1 mbar), cooled 
down in a dry desiccator and weighted (mempty). Freeze-dried samples were then introduced in 
these empty Eppendorf tubes which were weighted again (mfull) and dried under the same 
conditions as before for over 3 h. Final weight (mdried) was determined. 
Residual moisture was calculated as 
𝑚𝑓𝑢𝑙𝑙−𝑚𝑑𝑟𝑖𝑒𝑑
𝑚𝑓𝑢𝑙𝑙−𝑚𝑒𝑚𝑝𝑡𝑦
. 
7) Small-angle neutron scattering (SANS) 
NPs were nanoprecipitated in D2O at 2 mg/mL or resuspended in D2O after freeze-drying (1 
mg/mL, 5 wt. % trehalose). D2O was used to enhance the scattering contrast between 
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hydrogenated nanoparticles and deuterated solvent and to minimize the incoherent 
background from hydrogen.  
SANS experiments were performed at Institut Laue Langevin on D33 beamline (proposal 
number DOI: 10.5291/ILL-DATA.9-13-781). Samples were measured in Quartz optical Hellma 
cell of 1 mm path length thermalized at 25 °C with the thermostated sample holder available 
on the beamline. Four configurations were used to cover a q range from 1.5 x 10-3 Å-1 to 0.473 
Å-1. Detector distances of 2 m, 5.3 m and 12 m with the collimation 2.8, 5.3, 7.8 and 12.8 were 
used for respectively small angle (SA) (λ = 13 Å), medium angle (MA) (λ = 6 Å), wide angle (WA) 
(λ = 6 Å) and large angle (LA) (λ = 6 Å). Absolute intensities were obtained after radial average 
of the raw data and classical normalization using the LAMP software. 
8) Small-angle X-ray scattering (SAXS) 
NPs with low residual ethanol content were prepared as previously described but concentrated 
to 5 mg/mL after evaporation. These SQAd NPs were freeze-dried at 2.5 mg/mL in 5 wt. % 
trehalose as previously stated and concentrated twice during resuspension, reaching a final 
concentration of 5 mg/mL SQAd NPs in 10 wt. % trehalose. NPs with high residual ethanol 
content were prepared from nanoprecipitation of 333 µL SQAd ethanolic solution at 12 mg/mL 
into 1 mL of water and evaporated to reach a final concentration of 5 mg/mL.  
SAXS experiments were performed on the SWING beamline at the SOLEIL synchrotron 
(Saint-Aubin, France). We have checked that identical patterns were recorded if samples were 
loaded into quartz capillaries (diameter 1.5 mm, Glas Müller, Berlin, Germany) or flowed 
through a quartz capillary during beam exposure to avoid possible degradation under X-ray 
irradiation. Data were recorded at 12 keV in the scattering vector q-range 0.004 < q < 0.35 Å-1, 
using a bi-dimensional Eiger detector. The typical exposure time was 10 s. The beamline 
software Foxtrot was used for data collection and processing. For all samples, the scattering 
intensity was normalized with respect to the incident beam intensity, acquisition time and 
sample transmission. The scattering intensity I(q) was reported as a function of the scattering 
vector q = 4  sin  / where 2 is the scattering angle and  the X-ray wavelength. 
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9) Atomic force microscopy (AFM) 
Resuspended freeze-dried SQAd NPs were diluted to 100 µg/mL into water. 1 mL of this 
suspension was deposited on a piranha treated SiO2 wafer and left to adsorb for 1 h before 
being imaged by AFM with a Nanowizard 3 Ultra Speed from JPK Instruments (Berlin, Germany). 
The instrument was installed on an air-buffered table coupled to a dynamic antivibration device 
and enclosed in an acoustic box. Imaging was performed in water in AC mode with silicon 
nitride cantilevers of 0.8 ± 0.05 N/m spring constant and 230 ± 5 kHz resonance frequency 
(Bruker), with a radius of curvature less than 20 nm. Free amplitude oscillations of 10 to 15 nm 
were chosen, allowing a very high resolution of the imaged surface. Images were taken at scan 
rates of 1 Hz. Image processing (flatten, plane fit, edge and hole detection) was performed with 
the JPK Data Processing software (JPK Instruments). 
10) Cytotoxicity study 
HepG2 cells were grown in DMEM high glucose supplemented with 10 % FBS, penicillin (50 
U/mL) and streptomycin (50 µg/mL) at 37 °C, 5 % CO2, and divided to the sixth every 3-4 days. 
For cytotoxicity measurements, cells were seeded in 96-well plates at a density of 10,000 cells 
(in 100 µL) per well. After 24 h, 100 µL of medium containing increasing concentrations of NPs 
were added to each well. Cellular activity was assessed after 72 h of treatment by adding 20 µL 
of MTT solution (5 mg/mL in DPBS) and incubating 1 h before removing medium and dissolving 
formazan crystals with 200 µL DMSO. Absorbance was recorded at 570 nm. 
11) Hepatotoxicity study 
All procedures were conducted in compliance with the European legislation on animal 
experimentation (approved protocols 2013_0713_10166734 and 2016_085_6085). Male 
Hsd:ICR(CD-1) mice were obtained from Envigo (Gannat, France). Upon arrival, animals were 
housed in groups of five and allowed seven days to acclimatize under conventional housing 
conditions (water and food ad libitum, 12-hour light-dark cycle, controlled temperature). A mouse 
model of hepatic diseased mice was used for NPs hepatotoxicity assessment. First, blood samples 
were collected from the submandibular vein and mice were allowed seven days to recover before 
further procedure. Then, animals were anesthetized with 2 % isoflurane and injected intravenously 
(lateral tail vein) with SQAd NPs (2 mg/mL, 10 wt. % trehalose, 10 mL/kg). A mouse model of liver 
ischemia and reperfusion injury was performed according to the following procedure. After a midline 
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laparotomy, the portal triad was gently isolated with cotton buds and the blood was clamped off using 
a 6 x 1 mm microvessel clip (Micro Serrefines, Fine Science Tools, Germany), leading to a global 
liver ischemia confirmed by the organ blanching. After 40 min, the clip was removed, and the 
abdominal wall and skin were closed. Before awaking, mice were given 3 μg of buprenorphine 
subcutaneously as post-operative analgesia. Body temperature was maintained during the whole 
procedure with a heating pad, and the mouse was covered with a survival blanket during ischemia. 
24 h after reperfusion, blood was collected by cardiac puncture. Plasma samples were sent to 
Cerbavet (Wissous, France) for transaminases dosage.  
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III. Results 
Nanoparticles (NPs) were prepared using the so-called nanoprecipitation process, which 
consisted in dropwise addition of an ethanolic solution of SQAd into water. SQAd NPs presented 
a hydrodynamic diameter of 62 ± 10 nm and a monodisperse distribution (polydispersity index 
or PdI < 0.1). 
1) Optimization of nanoparticles freeze-thawing conditions using 
cryoprotectants 
Freeze-thawing tests were conducted as a preliminary experiment with SQAd NPs at a 
concentration of 1 mg/mL. Two freezing methods were tested: slow freezing for 24 h using a 
freezer (-30 °C) and fast freezing for 10 min in liquid nitrogen (-196 °C). As expected, SQAd NPs 
showed irreversible aggregation upon freezing in water, with the appearance of macroscopic 
particles in suspension after thawing and important increases in diameter and PdI (Figure 1A). 
To prevent NPs aggregation during freeze-drying process, cryoprotectants are generally added 
(13). Hence, four easily available carbohydrates were tested in this study for this purpose: a 
monosaccharide (dextrose), two disaccharides (sucrose and trehalose) and a polyol (mannitol) 
(14). Among them, trehalose was reported to be the most efficient cryoprotectant (9, 15, 16). 
After thawing, samples frozen in sucrose, trehalose and dextrose appeared as limpid solutions 
displaying Tyndall effect, while samples frozen in mannitol presented macroscopic aggregates. 
This was in good agreement with the values of the apparent hydrodynamic diameters measured 
after freeze-thawing: as shown in Figure 1A, addition of 5 wt. % sucrose or trehalose in the 
suspension perfectly preserved NPs diameter (diameter increase < 26%, PdI < 0.1), while 
dextrose has been less effective (238 % and 113 % diameter increase respectively after slow 
and fast freezing). With regards to mannitol, it was proved to be ineffective for our purpose, 
inducing instantaneous increase in diameter (+633 %) and PdI (0.2) even before freezing. 
Because sucrose and trehalose demonstrated acceptable cryoprotective activity at a 
concentration of 5 wt. %, we decided to investigate their cryoprotective ability at lower 
concentrations. Both disaccharides presented similar trends, with poor protection up to 1 wt. % 
(macroscopic aggregates and final hydrodynamic diameter over 600 nm) and satisfying 
protection over 2.5 wt. % (limpid solution with slight Tyndall effect), particularly under slow 
freezing conditions (size increase < 14 %) (Figure 1B and Figure 1C).  
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2) Characterization of freeze-dried NPs after redispersion 
Based on these preliminary tests, freeze-drying experiments were conducted in optimal 
conditions. It was observed that dry cakes from trehalose samples displayed well aerated 
appearance, while cakes from sucrose samples showed more compact forms (Supplementary 
Figure 1). However, resuspension occurred immediately after addition of water in all samples. 
The final suspensions were perfectly limpid, with a slight Tyndall effect. 
3) NPs size characterization by DLS 
As shown in Figure 2A, both sucrose and trehalose exhibited excellent lyoprotective activities, 
with highly reproducible size conservation at 5 wt. %. However, trehalose displayed a slightly 
better colloidal conservation at 2.5 wt.%. Taking this into account and considering the 
differences between the two cryoprotectants in term of cake aspects, trehalose was chosen for 
Figure 1 Apparent SQAd NPs diameter and polydispersity index (PdI) after freeze-thawing, as 
measured by dynamic light scattering (DLS), (A) before and after freezing in water and 5 wt. % 
carbohydrates solutions or (B) with increasing concentrations of sucrose or (C) trehalose. Data 
represent mean ± standard deviation (n=3). 
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further physico-chemical and biological investigations, even though NPs zeta potential was 
slightly increased by its addition (Figure 2B).  
4) NPs size characterization by small-angle neutron scattering (SANS) 
SANS patterns of freshly prepared SQAd NPs and freeze-dried SQAd NPs (after resuspension) 
are presented in Figure 3. Signals could be perfectly superimposed over a broad range of angles. 
The minor signal difference at small angles might be explained by the presence of some larger 
particles in the freeze-dried sample or by an excluded volume effect, which could appear for 
higher concentrations (2 mg/mL for freshly prepared NPs vs. 1 mg/mL for freeze-dried NPs), 
thus inducing a decrease in the scattered intensity. Nevertheless, the supramolecular 
organization of NPs could be considered as mostly identical before and after freeze-drying. 
Noteworthy, a small Bragg reflection around 0.075 Å-1 was visible on the diagram for both 
samples, indicating at the resolution of SANS experiments, a similar internal NPs structure for 
both preparations.  
A diameter of 42 nm and a PdI of 0.2 were found when fitting the curves considering a 
log-norm population of spheres. 
Figure 2 Effect of freeze-drying on SQAd NPs (A) apparent diameter, polydispersity index (PdI) and 
(B) zeta potential (ZP). Characterization by dynamic light scattering (DLS) before (white bars) or 
after slow freezing (red bars). Data represent mean ± standard deviation (n=3), ** indicates p<0.01, 
one-way ANOVA with Tukey’s post hoc test. 
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5) NPs morphology after freeze-drying 
Then, freeze-dried NPs were imaged by AFM in liquid after resuspension (Figure 4). Two kinds 
of objects were visible: numerous small regular round-shape NPs with size lower than 100 nm, 
adsorbed onto the silica surface as a compact layer, but also some bigger stick-shape assemblies 
as depicted by the white objects on the height picture. It appeared that the NPs were highly 
aggregated: based on previous size characterization, this was likely due to artefactual effects, 
resulting from sample dilution and adsorption on the SiO2 surface. Freeze-dried NP behaved as 
a viscoelastic material as shown by the high phase shifts observed on the phase image. NPs 
were flattened by their interaction with the surface, inducing lower heights and increased 
diameters compared to that extracted from DLS measurements. 
Figure 3 Small-angle neutron scattering 
(SANS) patterns of freshly prepared 
nanoparticles (NPs) at 2 mg/mL in D2O (black) 
and of freeze-dried NPs (after resuspension) 
at 1 mg/mL, 5 wt. % trehalose in D2O (red). 
The intensity of the freshly prepared NPs 
pattern was divided by two to normalize 
signals for 1 mg/mL. 
Figure 4 AFM height (A) and phase (B) images of freeze-dried nanoparticles (1 mg/mL, 5 wt. % 
trehalose) after resuspension and dilution in water (100 µg/mL). 
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6) Influence of residual ethanol on NPs size  
During the optimization of the experimental conditions described above, it was noted that 
immediately following nanoprecipitation and during the evaporation step, the time spent for 
removing ethanol strongly influenced the freeze-drying outcome, even though it did not affect 
the freeze-thawing after-effect. To explore this finding, the evaporation process was pushed to 
different limits and samples were characterized for residual ethanol content by a colorimetric 
assay relying on ethanol reduction by dichromate. As expected from the azeotropic nature of 
the water/ethanol mixture, a partial co-evaporation of water and ethanol occurred, and ethanol 
could not be fully evaporated. Depending on the evaporation time, residual ethanol content 
ranged from 0.1 % to 3.1 % (Figure 5A). The ethanol content after evaporation (before the 
freeze-drying step) could be fitted with a one-phase exponential decay model (r² = 0.96, 
𝑐𝑒𝑡ℎ𝑎𝑛𝑜𝑙 = 27 𝑒
−0.066 %𝐸𝑣𝑎𝑝 ). Of note, NPs diameter was not affected by ethanol content after 
evaporation and before freeze-drying (68 ± 16 nm) (Figure 5B). 
NPs samples from this library were then freeze-dried as previously optimized. As 
expected, the lyophilization drying step reduced the ethanol content in each sample (Figure 
5A). However, ethanol remained detectable in most samples with concentration up to 1 vol. %, 
indicating that ethanol molecules may remain adsorbed onto NPs surfaces. Interestingly, two 
distinct behaviours could be identified from Figure 5B, which represents the NPs apparent 
diameter before and after lyophilization : if the ethanol content was under 0.8 vol. %, the 
increase in diameter was low and the diameter after freeze-drying (76 ± 11 nm) remained close 
to the initial diameter (62 ± 8 nm); on the contrary, when the ethanol content exceeded 0.8 
vol. %, higher increases in diameter were witnessed, from + 44 % up to + 598 %. Hence, it was 
concluded that the ethanol content in NPs suspension dramatically impacted the freeze-drying 
outcome, as high ethanol content led to NPs aggregation during the freeze-drying process. 
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7) Influence of residual ethanol and freeze-drying on NPs 
supramolecular structure 
To investigate the influence of residual ethanol and freeze-drying on NPs supramolecular 
structure, two types of samples were prepared: samples containing high levels of residual 
ethanol (evaporation under 40 %, leading to over 2.0 % of ethanol in the suspension according 
to the exponential decay model) and samples containing almost no residual ethanol 
(evaporation over 67 %, leading to less than 0.3 % of ethanol in the suspension). It was 
observed that high ethanol content hindered the resuspension of the NPs after lyophilization. 
Thus, only ethanol-free samples were freeze-dried and analysed by small-angle X-ray scattering 
(SAXS). 
The SAXS diffraction pattern of SQAd NPs with low residual ethanol content showed 
three Bragg peaks at 0.0825 Å-1 (q0), 0.138 Å-1 (~q0√3) and 0.164 Å-1 (~2q0) (Figure 6A), 
characteristic of  an inverse hexagonal phase (HII) with a lattice parameter of 88 Å, in agreement 
with previous studies (17). The Bragg reflections in the SAXS pattern of SQAd NPs without 
residual ethanol are broader, revealing a lack of long-range order in the HII phase.  
Figure 5 Influence of ethanol evaporation on apparent NPs diameter before and after freeze-drying. 
(A) Residual ethanol concentration as a function of the evaporation percentage (defined as the 
percent change in liquid mass during the evaporation process) and (B) NPs apparent hydrodynamic 
diameter as a function of the residual ethanol concentration after evaporation (white dots) and after 
freeze-drying (red dots). Each dot represents a single sample. Curves correspond to least-squares 
regressions to one-phase exponential decay models. 
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The addition of trehalose did not impact the HII structure, as shown by the pattern of 
NPs with residual ethanol (Figure 6A). In contrast, the SAXS pattern of NPs rehydrated after 
freeze-drying displayed a broad band, around q~0.085 Å-1, very close from the previously 
identified q0, and a new peak at 0.13 Å-1 (Figure 6B), corresponding to a different phase. Based 
on previous data, this suggests the coexistence of the initial HII phase and a lamellar phase with 
a d-spacing of 48 Å. Indeed, a lamellar phase with the same d-spacing has already been found 
in SQAd NPs (17).  
8) Long-term conservation 
Under the best conditions (in terms of cryoprotection and ethanol content), the freeze-drying 
process did not affect the chemical structure of SQAd, which was checked by NMR (see 
Supplementary Figure 2). The residual moisture after lyophilization was also measured by 
the weight-on-drying method and was found to be low (1,07 ± 0,57 wt. %). 
As a result, freeze-dried samples could be characterized for stability upon long-term 
storage at room temperature (RT) or 4 °C. As can be seen on Figure 7, no change in apparent 
diameter, PdI or zeta potential could be recorded for up to two months of storage. However, a 
slight increase in size was noticed after three months storage at RT, which was not observed at 
4 °C. Hence, SQAd NPs displayed a very good long-term stability when stored at 4 °C. This study 
is still ongoing, with the aim of characterizing NPs stability for up to two years. 
Figure 6 Small-angle X-ray diffraction patterns of (A) squalene-adenosine nanoparticles (SQAd NPs) 
with or without residual ethanol, before freeze-drying, in water or in 10 wt. % trehalose, under static 
conditions, and (B) SQAd NPs without residual ethanol, before and after freeze-drying, in 10 wt. % 
trehalose (10 % T), under flow conditions. 
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9) NPs innocuity 
a. Samples osmolality 
Then, the osmolality of NPs solutions was measured before and after freeze-drying. Before 
freeze-drying, the low osmolality of the solution (14 ± 6 mOsm/kg) was attributed to the 
presence of NPs and traces of ethanol. The addition of 5 wt. % trehalose increased the tonicity 
to 151 mOsm/kg (theoretical calculation gives a contribution of 154 mOsm/kg). After freeze-
drying, a small decrease in tonicity was observed in 5 wt. % trehalose samples with or without 
NPs. Final NPs suspension was hypotonic (140 ± 4 mOsm/kg compared to 308 mOsm/kg for 
0.9 % saline) (Table 1). Interestingly, resuspension in 250 µL instead of 500 µL did not seem 
to affect NPs, which leads to solutions with higher tonicity and concentrated NPs.  
Table 1 Samples osmolality (mOsm/kg) before and after freeze-drying (FD). 
 Osmolality (mOsm/kg) 
Solution Before FD After FD 
5% trehalose 151 ± 2 142 ± 1 
NPs 14 ± 6 / 
NPs + 5% trehalose 165 ± 7 140 ± 4 
Figure 7 Colloidal stability of squalene-adenosine nanoparticles (SQAd NPs) after up to three months 
storage. (A) NPs apparent diameter, (B) PdI and (C) zeta potential, before freeze-drying (bef. FD), or 
after freeze-drying and storage at room temperature (RT) (circle, solid) or 4 °C (triangle, dotted) and 
resuspension. Data represent mean ± standard deviation (n=3), **** indicates p<0.0001, one-way 
ANOVA with Tukey’s post hoc test for comparison of stored samples with freeze-dried samples. 
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b. In vitro innocuity 
Knowing that SQAd NPs mostly accumulate in the liver after parenteral injection (8), we 
decided to carefully evaluate their potential hepatotoxicity. This was first done in vitro by 
checking NPs innocuity on HepG2, a human liver carcinoma cell line. Figure 8 shows that NPs 
induced no reduction on cellular activity after 72 h of treatment, even at very high 
concentration (400 µM). Importantly, no difference could be seen between freshly prepared 
NPs and freeze-dried NPs. 
 
c. In vivo innocuity 
A mouse model of liver ischemia and reperfusion injury was used to investigate the safety of 
SQAd NPs in animals with a decreased hepatic function. In that respect, a solution of SQAd NPs 
(freshly prepared or resuspended after lyophilization, 2 mg/mL, 10 wt. % trehalose) or vehicle 
(10 wt. % trehalose) was injected into mice prior to ischemia. While all control mice survived 
for 24 h after the surgery, only 67 % of the ones who received the freshly prepared SQAd NPs 
where still alive at that time point, showing some toxicity of these NPs on injured mice. On the 
opposite, all mice injected with freeze-dried NPs survived and no significant difference was 
observed in terms of aspartate transaminase (AST) and alanine transaminase (ALT) levels 
when comparing with those treated with vehicle (Figure 9). Hence, freeze-dried NPs appeared 
to be perfectly safe for intravenous injection in mice at the tested dose (20 mg/kg). 
Figure 8 HepG2 cells activity after 72 h 
incubation with freshly prepared or freeze-
dried squalene-adenosine nanoparticles 
(SQAd NPs) at different concentrations. 
Data represent mean ± standard deviation 
(n=3). 
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IV. Discussion 
Physical and chemical instabilities often occur during long-term storage of NPs in aqueous 
medium, which restricts their use (18). Freeze-drying NPs suspensions represents a useful 
solution to prevent aggregation and fusion of the particles, to maintain their size stability and 
to avoid their degradation during long-term storage.  
The aim of the present study was to determine appropriate conditions for long-term 
storage of SQAd NPs in order to ensure their stability, which is one of the most important 
aspects for translation of these NPs into a clinical setting. Another important aspect consisted 
in the design of SQAd NPs easy to manipulate before their administration. 
SQAd bioconjugates were first nanoprecipitated in water into NPs which were 
characterized by DLS technique. Of note, the size parameters reported in this study (diameter 
of 62 ± 10 nm, PdI < 0.1) were smaller than what was previously reported (diameter around 
120 nm, PdI = 0.13 (7)) due to differences in preparation conditions and dilution before 
measurements.  
As freezing is the first type of stress that NPs will face during the freeze-drying process, 
freeze-thawing experiments are often conducted as a preliminary simple and predictable 
Figure 9 Plasma aspartate (AST) and alanine (ALT) transaminases levels in mice subjected (+) or 
not (-) to liver ischemia. NPs (20 mg/kg, 10 % wt. trehalose) or vehicle (10 % wt. trehalose) were 
injected 15 min before proceeding to a 40-min global hepatic ischemia. Plasma samples were 
collected 24 h after reperfusion on surviving mice. Bars represent mean ± standard deviation. 
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approach for determining suitable cryoprotectants and their optimal concentrations (19). Most 
popular cryoprotectants used for freeze-drying nanosuspensions include sugars (glucose, 
sucrose, trehalose and mannitol), which are known to vitrify under a certain temperature (10). 
As a result, they are thought to form a glassy matrix in which NPs are immobilized and cannot 
aggregate (glass dynamics hypothesis, formerly named vitrification theory (20)). With SQAd 
NPs, mannitol induced direct NPs aggregation and dextrose was unable to protect them 
properly from freezing stress, while sucrose and trehalose were found to display good 
cryoprotectant activities at this concentration. As expected, high concentrations of 
carbohydrates were beneficial (ie. 5 wt.%). Even though fast freezing is sometimes claimed as 
the more appropriate for freezing nanosuspensions (13), there is no real consensus on this 
question (21). In the present study, slow freezing at -30 °C revealed slightly better than fast 
freezing in liquid nitrogen for conserving NPs size. An explanation would be that, during 
freezing, two phases appear due to the moving of the freezing front: the first one constituted of 
ice crystals and the second one containing a cryo-concentrated solution. During this 
phenomenon, NPs accumulate in the cryo-concentrated liquid phase mainly through the 
cryoprotectants which physically adsorb on their surface. When the freezing rate is slow 
enough, cryoprotectants could move totally into the cryo-concentrated liquid phase. This led to 
increased concentration of cryoprotectant within the liquid phase, thus preventing aggregation. 
During fast freezing rate, cryoprotectants have no time to fully migrate into the cryo-
concentrated liquid phase. Therefore, their concentration is too low, and they are not efficient 
in preventing NPs aggregation. It must be noted that this explanation is valid only for low 
cryoprotectant concentration, which might explain why such a difference is observed between 
slow and fast freezing only at 2.5 wt. % of cryoprotectant, but not at 5 wt. % (13).  
With regard to the choice of cryoprotectant, the best outcome was obtained with 
trehalose, which was already described as the best cryoprotectant for other lipid-based 
nanoparticles (14). This was attributed to its increased interaction with water molecules and 
its highest glass transition temperature (22). 
After freeze-drying, the lyophilised NPs appeared as a white solid “soft cake” which 
could be easily redispersed in water without any aggregation. Freshly prepared SQAd NPs 
versus lyophilized and reconstituted ones were compared using different techniques. Size 
evaluation by DLS indicated conservation of their diameter and characterisation using SANS 
technique led to superimposed diagrams, confirming identical sizes. The scattering intensity 
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was typical of a suspension of a log norm distribution of spherical particles (23). The 
discrepancy in size observed between the two techniques (~ 60 nm vs. ~ 40 nm for DLS and 
SANS respectively) may arise from their specificities: DLS gives access to the NPs hydrodynamic 
diameter, while SANS measures the contrast formed by hydrogen atoms in a deuterium 
background. The small increase in SANS signal intensity at small angles could be linked to the 
presence of some stick-shape assemblies, also evidenced by AFM. The Bragg peak visible 
around 0.075 Å-1 with SANS seemed to correspond to the one obtained for the first order of the 
hexagonal phase by SAXS (0.08 Å-1). However, the lamellar phase detected by SAXS after 
lyophilization was not visible by SANS. All these converging data confirmed the successful 
preservation of the NPs after freeze-drying. 
In the present study, we also investigated how the presence of residual ethanol (used 
during the nanoprecipitation process) in NPs suspensions could affect the lyophilization. 
Several factors were previously reported to perturb nanomedicines structure during freeze-
drying such as mechanical stress during ice growth (24, 25), change in osmolarity (26), 
interaction with sugar particles (27) or loss of structural water (11). However, the effect of 
removing residual solvent has never been discussed yet in the literature. Indeed, the presence 
of residual solvent after nanoprecipitation is most of the time overlooked, with no titration of 
residual solvent after evaporation or dialysis (28), and only few efficient methods for complete 
solvent elimination were reported (29). During this study, it was clearly observed that the 
presence of residual ethanol led to poor resuspension after freeze-drying. Since the presence of 
residual ethanol could affect the supramolecular structure of squalene based NPs (23) and since 
we anticipated that freeze-drying process would partly remove residual solvent, we decided to 
explore the NPs structure before and after this process. Therefore, it was observed that after 
the evaporation step, NPs in suspensions containing residual ethanol displayed an inverse 
hexagonal phase. This phase consisted of the assembly of SQAd bioconjugates within the NPs, 
forming thus cylinders whose aqueous core was surrounded by the hydrophilic adenosine 
moieties linked to the hydrophobic chains of squalene, which arranged on a two-dimensional 
hexagonal lattice (17). In that respect, increasing the evaporation step decreased the long-range 
order of the structure, which may be attributed to the small size of the NPs entailing short 
coherence lengths and structural distortions at the interface. Of note, a decrease in size of 
squalene based NPs upon withdrawal of ethanol has been previously reported (23). After 
freeze-drying and resuspension, the hexagonal phase appeared to coexist with a lamellar phase. 
The occurrence of this lamellar phase has been previously linked to the increase in the mean 
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area of the polar adenosine moieties at the water/SQAd interface (17). It might be hypothesized 
that the insertion of a few trehalose molecules between the adenosine head groups, promoted 
by hydration of the freeze-dried powder, could expand their mean lateral area as shown, for 
example, by Andersen et al. for sugar-phospholipid membrane interactions at low sugar 
concentrations (5-10 %) (30).  
Regarding long-term stability, storage at 4 °C showed no modifications of NPs physico-
chemical characteristics after resuspension, which meets industrial requirements in terms of 
transport and conservation. 
A final study was conducted to guarantee the innocuity of NPs both in vitro and in vivo. 
Indeed, as the major aim in freeze-drying nanomedicines is to make NPs suitable for clinical 
applications (31), it seemed crucial to investigate this issue. As a first step, osmotic pressure 
measurements were performed on SQAd NPs solutions after resuspension and revealed 
hypotonic solutions. This is an interesting point because it allows for tonicity adjustment 
without dilution before parenteral injection. 
Moreover, liver safety had to be considered as SQAd NPs accumulate in the liver after 
intravenous injection (8). Preliminary in vitro experiments were therefore performed on 
cultured hepatocytes. HepG2 cells were selected because they represent a well-accepted model 
of human hepatocytes and are easy to handle under in vitro conditions. In addition, the HepG2 
cells have been used as a liver-specific cell line to predict hepatotoxicity of drugs in general (32) 
and nanoparticles in particular (33-35). Lyophilised SQAd NPs did not exhibit any toxicity in 
vitro after 72 h of treatment on HepG2 cell line. While intravenous injection of freshly prepared 
SQAd NPs induced some mortality on liver injured mice, freeze-dried SQAd NPs were shown to 
be perfectly safe on the same animal model. Higher residual ethanol contents in freshly 
prepared NPs may explain this difference. This result further strengthens the progress towards 
SQAd NPs clinical application. 
 
V. Conclusion 
Preserving the colloidal stability of nanoparticles before clinical translation is mandatory. This 
has been successfully performed by lyophilization of squalene-adenosine nanoparticles and the 
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demonstration has been done that the diameter, the zeta potential and the supramolecular 
structure of the particles were preserved. Additional in vitro and in vivo experiments have 
established the safety of this nanoformulation towards the liver tissue, the major organ of 
nanoparticles accumulation after systemic intravenous administration. 
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VII. Supplementary materials 
 
Supplementary Figure 1 SQAd NPs 
samples after freeze-drying, using 
5 % wt. sucrose (left) or 5 % wt. 
trehalose (right).  
Supplementary Figure 2 1H NMR spectra of SQAd bioconjugate dissolved in chloroform-d (black 
spectrum) or formulated as NPs, freeze-dried in 5 % wt. trehalose and dissolved in chloroform-d (red 
spectrum). A drop of D2O was added in each sample. 
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Discussion Générale 
The original aim of this thesis was to evaluate the pharmacological efficacy of SQAd NPs on liver 
ischemia and reperfusion. The main hypothesis was that SQAd NPs would protect the liver from 
this pathology, which was supported by three main arguments.  
First, an increase of endogenous extracellular adenosine was shown to happen during 
liver ischemia, as a result of transcriptional repression of ENTs (1) as well as CD39 (2) and CD73 
(3) overexpression, and this increase in adenosine protected the liver against ischemia-
reperfusion injury (1,4). More specifically, adenosine acted via its four receptors (A1, A2A, A2B, 
A3) and particularly by A2A receptor which down-regulates inflammation (5–8) and by A2B 
receptor which protects hepatocytes (1,9). 
Secondly, SQAd NPs had previously been proven to be effective against cerebral 
ischemia on mice (10), which admittedly was another organ but had, however, similar 
pathological features including ATP depletion and cellular acidosis during ischemia, as well as, 
ROS generation and inflammation during reperfusion (11). 
Thirdly, SQAd NPs had been found  to accumulate in important quantities in the liver 
after intravenous injection (12) without triggering any hepatotoxic effect in healthy mice (10). 
Moreover, this accumulation of SQAd NPs resulted in the release of free adenosine in the liver 
tissue (12). 
Based on these evidences, it was decided to test the pharmacological efficacy of SQAd 
NPs on a mouse model of global liver ischemia. 
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I. SQAd NPs for the treatment of liver ischemia 
1) SQAd NPs and liver ischemia 
A model of global liver ischemia was set up as shown on Figure 1A. Briefly, mice portal triad 
was clamped for 25 min before reperfusion. SQAd NPs were injected at different time points 
and blood samples were collected 6 h after reperfusion for ALAT quantification (Figure 1B). 
All mice survived to 6 h reperfusion, except when the treatment was injected 10 min 
before ischemia. In that case, an increase in the number of dead mice was observed during 
ischemia or reperfusion as a result of the injection of SQAd NPs, whatever the injected dose 
(Figure 1F). In terms of ALAT levels, no effect could be seen when the treatment was injected 
30 min after reperfusion (Figure 1C) or 24 h before ischemia (Figure 1D) (same levels as 
control), while a significative increase was observed when the treatment was injected 10 min 
before ischemia at the highest dose (Figure 1E). Even though the number of mice was limited 
because these experiments were of preliminary nature, it likely appeared that the injection of 
SQAd NPs suspensions 10 min before ischemia resulted in some liver toxicity. Noteworthy, 
other preliminary experiments have shown that SQ NPs (NPs prepared with squalenylacetic 
acid under the same nanoprecipitation conditions as SQAd NPs) presented similar toxicity (data 
not shown). 
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Figure 1 Effect of SQAd NPs at different doses and times of injection on a mouse model of global liver 
ischemia. (A) Mice were anesthetized with isoflurane, opened by laparotomy and subjected to global 
ischemia by clamping the portal triad for 25 min. After 6 h of reperfusion, blood was collected and ALAT 
levels were measured. (B) NPs were injected at different time points. (C-E) Plasma ALAT levels (UI/L) 
of mice before (black dots) and after (colored dots) global ischemia and treatment by intravenous 
injection of SQAd NPs suspensions at different doses 24 h (C) or 10 min (D) before ischemia, or 30 min 
after ischemia (E). Each dot represents a mouse. Bars represent mean ± standard deviation. (F) All mice 
survived to 6 h reperfusion, except when the treatment was injected 10 min before ischemia. Each bar 
represents four mice. 
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This toxicity on ischemic livers could arise from the different components of the NPs:  
1. SQAd bioconjugates; 
2. Ad released from NPs; 
3. SQ released from NPs; 
4. Uncompletely evaporated ethanol used during the nanoprecipitation process; 
5. NPs assemblies due to complement activation. 
But, previous detailed toxicity studies have demonstrated the overall safety of SQAd NPs 
on healthy mice and, interestingly, no significant complement activation was observed either 
(10). This is the reason why we have explored the possible involvement of residual ethanol in 
SQAd NPs arising from the nanoprecipitation process, which could eventually increase the 
toxicity in animals with ischemic liver.  
 
2) Ethanol toxicity 
Ethanol is listed by the FDA as a class 3 solvent, which means that it is considered as less toxic 
in acute or short-term studies in humans and negative in genotoxicity studies. Ischemic livers, 
however, might be more sensitive to ethanol, especially if it is delivered intracellularly in NPs. 
In order to explore this hypothesis further, we measured the quantity of residual ethanol 
in NPs suspension. Results were presented in Chapter 2, Figure 5A. If evaporation was not 
pushed above 50 % (meaning evaporation of more than 0.5 mL when preparing 1 mL of final 
NPs suspension), residual ethanol was found to be over 1 vol. %. Of note, before this finding 
(and in particular for experiments on liver ischemia presented above), ethanol evaporation was 
not closely monitored and was considered to be complete over roughly 20 % evaporation. 
A rapid calculation can give us an idea of the quantity of ethanol this represents once 
systemically injected in mice. Let us consider a suspension with 1 vol. % ethanol.  
𝑐𝑠𝑢𝑠𝑝𝑒𝑛𝑠𝑖𝑜𝑛
𝐸𝑡𝑂𝐻  = 1 𝑣𝑜𝑙. % = 0.8 𝑤𝑡. % = 8 𝑔/𝐿 
The injected volume corresponds to 10 mL/kg (or 0.01 L/kg), and mice have a blood 
volume of around 60 mL/kg (0.06 L/kg). 
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As a result, the concentration of ethanol in the blood right after injection is 
𝑐𝑏𝑙𝑜𝑜𝑑
𝐸𝑡𝑂𝐻  = 𝑐𝑠𝑢𝑠𝑝𝑒𝑛𝑠𝑖𝑜𝑛
𝐸𝑡𝑂𝐻  × 𝑣𝑠𝑢𝑠𝑝𝑒𝑛𝑠𝑖𝑜𝑛 ÷  𝑣𝑏𝑙𝑜𝑜𝑑 = 8 × 0.01 ÷ 0.06 = 1.3𝑔/𝐿 
Hence, the concentration of ethanol in mice blood right after NPs suspension injection is 
around 1.3 g/L, which is far to be negligible regarding toxicity in liver ischemic animals. Indeed, 
since SQAd NPs accumulate in the liver after intravenous injection, this may lead to the delivery 
of high doses of ethanol in the already ischemic tissue. 
 
3) Freeze-drying as a way of removing ethanol 
As described in Chapter 2, freeze-drying SQAd NPs represents an efficient way of 
minimizing residual ethanol (Chapter 2, Figure 5A). 
 Consequently, the effect of NPs containing no more residual ethanol (or at very 
low percentages) could be assessed again on mice with liver ischemia. As shown on Figure 2 
(and Chapter 2, Figure 9), the previously described toxicity seemed to be abolished after 
ethanol removal by freeze-drying. 
  
 It is worth noting that the presence of residual ethanol (or other solvent like THF or 
acetone) in suspensions after nanoprecipitation was rarely looked at. Most of the time, residual 
solvent is removed by evaporation under reduced pressure based on the fact that its boiling 
point is lower than the one of water, and then considered to be absent even though no titration 
has been realized (13). Our study shows that, even if this solvent is considered as of low toxicity 
Figure 2 Mice survival 
after 40 min ischemia. 
Freshly prepared and 
freeze-dried SQAd NPs 
were injected 15 min 
before ischemia at a dose 
of 20 mg/mL. 
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(ethanol, acetone and DMSO are class 3 solvents according to the FDA), overlooking this issue 
can lead to dramatic results in some circumstances (depending on the studied pathology, on 
NPs accumulation in an organ, etc). If dialysis is sometimes used to overcome this problem, we 
proposed here freeze-drying as a way to both remove ethanol and prepare NPs under a stable 
form and an easy-to-use formulation (Chapter 2). To our knowledge, such an approach had 
never been presented as a solution to rise above the problem of residual solvent in 
nanoparticles. Moreover, we could show during Chapter 2 that ethanol itself needed to be 
closely monitored for a complete success of the freeze-drying process (the presence of high 
residual quantities of ethanol induced NPs aggregation during freeze-drying). These findings 
on the reciprocal influence between ethanol and freeze-drying might be very useful for the 
nanomedicine community. 
Getting back to our original aim, these SQAd NPs still had no efficacy in treating liver 
ischemia, as could be seen by ALAT titration (Chapter 2, Figure 9). This meant that our starting 
assumption was probably false, notwithstanding the strong rational presented above: SQAd 
NPs could not treat liver ischemia under tested conditions. Hence, a deeper understanding of 
SQAd NPs mechanism of action was urgently needed before moving into new applications.  
 
II. Understanding SQAd NPs mechanism of action 
As presented in the Chapter 1, SQAd NPs form an intracellular reservoir of adenosine (Figure 
3A). The above in vitro study has led us to the important conclusion that SQAd NPs act as a 
prodrug and that the active substance is free adenosine released from this prodrug after 
intracellular processing. 
Hence, we now have these two facts: 
i. Free endogenous adenosine has protective effects on ischemic livers; 
ii. SQAd NPs administration leads to free adenosine release. 
A simplified reasoning would conclude again from these two facts that SQAd NPs should 
treat liver ischemia and reperfusion. However, this is not the case. How to explain this syllogism?  
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1) SQAd NPs vs. free adenosine vs. adenosine receptor agonists and 
antagonists 
Even though endogenous adenosine was shown to be released during ischemia and have 
protecting effects, protective effects of exogenous adenosine on liver ischemia in vivo was only 
shown once 20 years ago (infusion of adenosine for 20 min prior to 90 min right lobe ischemia 
in rats led to reduced ALAT, ASAT and LDH levels) (14). The main reason why exogenous 
adenosine has shown so little results so far was due to its rapid metabolization in the blood 
circulation in vivo which do not allow it enough time to produce any effect on liver ischemia 
(Figure 3B). 
The other studies that claim adenosine efficacy against liver ischemia and reperfusion 
injury actually target a single adenosine receptor with specific agonists or antagonists (Figure 
3C). This case is very far from the use of free adenosine as this natural ligand binds the four 
receptors simultaneously, with a much more complex effect on the cells, eventually related to 
the dynamic overexpression or, on the contrary, downregulation of these receptors after 
adenosine binding. Moreover, using a specific agonist or antagonist can change the binding 
equilibria of endogenous adenosine with its four receptors and may lead to contradictory 
effects, too (15). As a result, it might be abusive to try to extrapolate studies using adenosine 
receptors agonists or antagonists to adenosine itself. 
In the case of SQAd NPs, however, it seems that we should be rather close from the 
endogenous release observed during ischemia. Indeed, SQAd NPs were shown to act as an 
intracellular reservoir of adenosine which is released in the extracellular space, in the same 
way as endogenous adenosine is released from ischemic cells. The main difference between the 
two situations could however arise from the quantities that are released extracellularly and the 
equilibrium between intracellular and extracellular concentrations. 
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2) Adenosine release from SQAd NPs under ischemia 
Another possible explanation for the lack of efficacy of SQAd NPs for the treatment of liver 
ischemia and reperfusion injury might be that, under ischemic or post-ischemic conditions, 
cells are not able to internalize SQAd NPs or release adenosine from SQAd bioconjugate. Indeed, 
ischemia induces hypoxia and cell energy depletion. SQAd NPs internalization was proven to 
require energy (16) and, even though SQAd cleavage was shown to happen simply under acidic 
conditions (Chapter 1 Figure 4), it may be more efficiently catalyzed by enzymes in cells and 
thus be slowed down during ischemia. 
Figure 3 Proposed mechanisms of action of SQAd NPs (A), free adenosine (B) and adenosine receptor 
agonist (C). (A) After injection into the blood stream, SQAd NPs are internalized by cells and leading to 
an intracellular reservoir of SQAd bioconjugates, slowly releasing adenosine into the cell. Adenosine is 
then effluxed outside the cell, where it can bind adenosine receptors on neighbouring cells, inducing the 
activation of various signaling pathways which may interfer. (B) When free adenosine is injected in the 
blood stream, it is rapidly degraded and eventually only has an effect on cells located near the site of 
injection and during a very short period of time. (C) Specific adenosine receptor agonists or antagonists 
(e.g. A2A receptor agonist in the figure) usually present enhanced pharmacokinetics compared to free 
adenosine and reach their target all over the body. They selectively bind one of the adenosine receptors 
and induce the specific signaling pathway of this receptor. 
  Discussion Générale  
105 
It would be interesting to check these hypotheses in vitro by studying adenosine release 
from cells treated with SQAd NPs under hypoxic conditions. 
 
3) Liver is not the brain 
The last argument in favor of a possible protective effect of SQAd NPs on liver ischemia 
reperfusion injury was that NPs had already proven effective on cerebral ischemia and that 
both pathologies are very close at a cellular and molecular level, whatever the organ. 
However, the lack of response from our therapeutic strategy on the liver means that this 
postulate was probably wrong. 
A first difference between the brain and the liver may arise from SQAd biodistribution 
in vivo. Indeed, after SQAd NPs intravenous injection, very important quantities of the 
bioconjugate were found in the liver, while no bioconjugate could be found in the brain (12). 
Liver accumulation is rather usual for NPs of this size but, in the case of SQAd NPs, 
internalization was also shown to occurs through LDL receptors (Chapter 1, Figure 3D) which 
are highly expressed in the liver (according to the Human Protein Atlas). This organ was shown 
to be responsible for a very large part of LDL clearance (17), so it is not surprising that it is also 
responsible for an important part of SQAd NPs clearance. This accumulation of SQAd into the 
liver was first seen as an advantage for delivering important quantities of adenosine to this 
organ and treating liver ischemia and reperfusion. Instead, it seems unfavorable (or ineffective) 
under these conditions.  
Finally, another difference between the two organs is that different cell types may play 
crucial role in response to ischemia and reperfusion. In the brain, the protective action of SQAd 
NPs was shown to be mainly due to interactions with endothelial cells (10). Indeed, adenosine 
would induce vasodilation and thus a better oxygenation during reperfusion, due to a dramatic 
decrease in the number of clogged brain capillaries. In the liver, adenosine is claimed to protect 
from ischemia via its action on inflammatory cells (mainly NKT cells (7,8)) and on hepatocytes 
(9,18). And, still more importantly, adenosine is known to be vasodilator for most vascular 
tissues except hepatic portal vein (19). 
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III. Conclusion and perspectives 
As a conclusion, we have to admit that predicting the therapeutic efficacy of SQAd NPs can be 
extremely hard, for different reasons: 
• Adenosine pharmacology is extremely complex, with four receptors having 
different but complimentary actions and being expressed on different levels 
depending on space (the type of cell) and time (physiology vs. pathology); 
• The delivery of adenosine as NPs changes the pharmacokinetics and 
biodistribution of this nucleoside to such a point that it is hard to extrapolate any 
results obtained with adenosine to SQAd NPs. 
 
Even if some questions remain, our study has brought extremely valuable information 
for future applications: 
1. A better understanding of SQAd NPs mechanism of action in vitro: 
• We showed that SQAd NPs or SQAd bioconjugates had no direct interactions with 
adenosine receptors; 
• We highlighted an original mechanism of entry dependent on LDL receptors; 
• We unveiled the formation of an intracellular reservoir of adenosine via SQAd 
accumulation, SQAd cleavage under acidic conditions and adenosine release in the 
extracellular space; 
• We checked that adenosine proceeding from this reservoir could activate 
adenosine receptors on neighboring cells; 
• We established these results on a hepatocyte cell line and extended them to brain 
endothelial cells. 
2. A method for enhancing SQAd NPs formulation by freeze-drying: 
• We tuned freeze-drying conditions for obtaining perfect conservation of the NPs 
properties by varying the nature and concentrations of cryoprotectants, as well as 
the freezing process; 
• We deeply characterized the physico-chemical properties of freeze-dried NPs 
via different techniques including dynamic light scattering, small-angle X-ray or 
neutrons scattering and atomic force microscopy; 
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• We investigated the influence of ethanol on the freeze-drying process and 
showed that, under some conditions, freeze-drying could be used as a way of 
removing ethanol from NPs preparations; 
• We checked the innocuity of NPs after freeze-drying and resuspension both in 
vitro and in vivo; 
• We followed freeze-dried NPs stability over several months. 
 
These findings can be combined with the lack of efficacy observed on liver ischemia and 
reperfusion injury to better orientate future research on SQAd NPs therapeutic applications. 
We believe that SQAd NPs should deserve to be investigated for beneficial effects on heart 
ischemia for the following reasons. 
A first argument comes from SQAd NPs mechanism of action. As SQAd NPs act as a 
prodrug which main effect in vitro seems to be a prolonged release of extracellular adenosine, 
SQAd NPs efficacy could be evaluated on pathologies currently treated with medicines which 
also induce an increase of extracellular adenosine. Dipyridamole, which blocks adenosine entry 
into the cells, is one of these drugs. It inhibits platelet aggregation and induces vasodilation, and 
thus is used for treating thrombosis and heart ischemia after myocardial infarction.  
Secondly, the discussion held above led us to conclude that the biodistribution of SQAd 
NPs in the targeted organ should not be too different from the one in the brain, and that 
endothelial cells should play an important role in the pathology. These two facts are verified for 
heart ischemia. 
Last but not least, the freeze-dried formulation allows the use of SQAd NPs in emergency 
cases, which is a prerequisite in treating myocardial infarction. 
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Ô cher Zetasizer, que ferions-nous sans toi ? 
Tu déchaines la fureur d’Elias notre roi 
Car nous tous, pauvres gueux, doctorants et stagiaires 
Nous battons sans répit pour ton petit laser. 
  
Ô, que ne donnerais-je point pour ta compagnie, 
Quelques heures avec toi, ou bien toute une nuit, 
Regarder ton écran, mesurer mon zêta, 
Sont pour moi un bonheur qui ne se compare pas. 
  
Car oui, je vous l’avoue, j’aime tant ces mesures, 
Cette petite salle odorante et obscure 
Où l’on ne peut rien faire mis à part s’ennuyer, 
  
Que sur le GRR je réserve des heures 
Et tant pis pour tous ceux dont je fais le malheur, 
Le zêta est à moi, jamais vous ne l’aurez ! 
 
Université Paris-Saclay           
Espace Technologique / Immeuble Discovery  
Route de l’Orme aux Merisiers RD 128 / 91190 Saint-Aubin, France  
 
Titre : Avancées dans le développement pré-clinique des nanoparticules d’adénosine-squalène : mécanisme d’action et formulation 
Mots clés : nanomédicine ; adénosine ; squalène ; bioconjugaison ; prodrogue ; délivrance de médicament  
Résumé : L’adénosine est une molécule dotée d’un fort potentiel 
thérapeutique, mais présentant néanmoins un temps de demi-vie 
plasmatique extrêmement court qui limite de manière sérieuse 
son efficacité. Comme présenté dans l’introduction 
bibliographique de cette thèse, cette difficulté peut être surmontée 
grâce à l’utilisation de systèmes de délivrance de médicaments à 
base de lipides. L’adénosine peut en effet être soit encapsulée 
dans des liposomes, soit simplement couplée à un lipide. Parmi 
les « lipidizations » de l’adénosine, la « squalénisation », 
notamment, a favorablement modifié la biodistribution de cette 
substance active. Cette technique consiste à coupler l’adénosine 
à une molécule lipophile dérivée du squalène, générant ainsi des 
bioconjugués ayant la capacité de s’auto-assembler spontanément 
en milieu aqueux sous forme de nanoparticules d’une centaine de 
nanomètres de diamètre. L’injection de ces nanoparticules 
d’adénosine-squalène (AdSQ) par voie intraveineuse a donné des 
résultats très prometteurs pour le traitement de l’ischémie 
cérébrale et du traumatisme de la moëlle épinière. Ainsi, l’objectif 
de cette thèse a consisté à faire progresser le développement pré-
clinique de ces nanomédicaments suivant deux axes principaux : 
l’étude du mécanisme d’action et l’amélioration de la 
formulation. 
 
De ce fait, le premier chapitre de cette thèse présente les résultats 
obtenus lors de l’étude in vitro du mécanisme d’action des 
nanoparticules d’AdSQ. Les travaux ont montré que ces 
nanoparticules d’AdSQ n’interagissaient pas directement avec les 
récepteurs à l’adénosine, mais formaient un réservoir 
intracellulaire d’adénosine. En effet, après internalisation, le 
bioconjugué d’AdSQ est clivé pour libérer l’adénosine. Celle-ci 
finit par être effluée par les cellules vers le milieu extracellulaire, 
où elle peut ainsi activer les récepteurs spécifiques situés au niveau 
des membranes des cellules avoisinantes. Après étude du 
mécanisme, l’amélioration de la formulation de ces nanoparticules 
a été explorée et décrite dans le deuxième chapitre. Les efforts ont 
été principalement concentrés sur la lyophilisation de la suspension 
nanoparticulaire, afin de proposer une formulation stable dans le 
temps et facile d’utilisation dans le cadre médical. Les conditions 
utilisées ont aboutit au bon maintien des propriétés physico-
chimiques des nanoparticules et l’obtention de solutions injectables 
sans risque chez l’animal. Dans son ensemble, ce travail de thèse a 
permis d’élargir les perspectives d’application des nanoparticules 
d’AdSQ grâce à une meilleure compréhension de leur mécanisme 
d’action ainsi que la mise au point d’une formulation plus adaptée 
aux besoins cliniques. 
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Abstract : Adenosine has a high therapeutic potential but its 
extremely short half-life in blood seriously impairs its efficacy. 
As presented in the literature review, this difficulty can be 
overcome by using lipid-based drug delivery systems. Indeed, 
adenosine can be encapsulated into liposomes or conjugated to a 
lipid. In particular, among adenosine « lipidizations », the so-
called « squalenoylation » has been shown to enhance adenosine 
biodistribution. This technique consists in coupling adenosine to 
a lipophilic squalene derivative, hence generating bioconjugates 
which are able to spontaneously self-assemble as nanoparticles of 
100 nm of diameter in aqueous solution. Intravenous injection of 
these squalene-adenosine (SQAd) nanoparticles produced 
promising results for treating cerebral ischemia and spinal cord 
injury. Thus, the aim of this thesis was to push forward the pre-
clinical development of these nanomedicines following two main 
directions: unveiling their mechanism of action and enhancing 
their formulation. 
 
Thereby, the first chapter of this thesis presents results obtained 
when studying in vitro SQAd nanoparticles mechanism of action. 
This work has shown that SQAd nanoparticles did not interact 
directly with adenosine receptors, but formed an intracellular 
reservoir of adenosine. Indeed, after internalisation, SQAd 
bioconjugates are clived into free adenosine. This molecule is then 
released by the cells in the extracellular medium, where it can 
activate specific membrane receptors on neighbouring cells. After 
studying the mechanism of action, we explored how to enhance the 
formulation. Results are described in the second chapter. We focus 
our efforts on freeze-drying the nanoparticles suspension, in order 
to offer a stable and easy-to-use formulation. Selected conditions 
led to a good conservation of nanoparticles physico-chemical 
properties and obtention of solutions which could be safely injected 
in the animal. Overall, this work has widen the field of possible 
applications for SQAd nanoparticles thanks to a better 
understanding of their mechanism of action and the development 
of a more clinically-adapted formulation. 
 
 
 
 
